ADC-0 46-INI 
IND #: 119,232
[STUDY_ID_REMOVED] 
Page 1 of 55 Therapeutic effects of intranasally -administered insulin (INI)  
in adults with  amnestic mild cognitive impairment (aMCI) o r mild 
Alzheimer’s disease (AD)  
Protocol #: ADC -046-INI 
IND #: 119,[ADDRESS_449992] DIRECTOR  / 
IND SPONSOR  COORDINATION & DAT A 
MANAGEMENT CENTER  
Suzanne Craft, Ph.D.  
Wake Forest University  
School of Medicine  
Medical Center Boulevard  
Winston -Salem, NC  [ZIP_CODE] -1207 Paul Aisen, M.D.  
ATRI  Director  
Alzheimer’s Therapeutic Research Institute 
(ATRI) 
University of Southern [LOCATION_004]  
PROTOCOL VERSION  VERSION DATE  
Final Protocol v 5.0 05DEC2016 

    
ADC -046-INI 
IND #: 119,[ADDRESS_449993] iance  .................................................................................................. 16 	
3.4 	Statistical Analyses  ........................................................................................................ 16 	
3.5 	Results: Cognitive and Functional Outcome Measures  ................................................. 17 	
3.6 	Results: AD Biomarkers  ................................................................................................ . 18 	
3.7 	Results: FDG -PET CMRglc  ...........................................................................................  18 	
3.8 	Safety and Compliance  .................................................................................................. 19 	
3.9 	Implications  .................................................................................................................... 20 	
4.0 	STUDY DESIGN RATIONA LE ..........................................................................................  20 	
4.1 	Rationale for Pop ulation Selection ................................................................................. 20 	
4.2 	Rationale for Dosage Selection  ..................................................................................... 20 	
4.3 	Rationale for Primary and Secondary Outcome Measures  ............................................ 21 	
4.4 	Rationale for Length and Design of Trial  ....................................................................... 21 	
4.5 	Rationale for Magnetic Resonance Imaging  .................................................................. 21 	
4.6 	Rationale for Biofluids  .................................................................................................... 22 	
5.0 	STUDY OVERVIEW  .......................................................................................................... 22 	
5.1 	Study Population  ............................................................................................................ 23 	
5.2 	Diagnosis Criteria  ........................................................................................................... 23 	
5.3 	Inclusion Criteria  ............................................................................................................ 24 	
5.4 	Exclusion Criteria  ........................................................................................................... 24 	
5.5 	Recruitment and Retention Strategies  ........................................................................... 25 	
6.0 	STUDY TIMELINE ............................................................................................................. 26 	
7.0 	DESCRIPTION OF STUDY VISITS ................................................................................... 26 	
7.1 	Pre-Screening  ................................................................................................................ 26 	
7.2 	Screening (Visit  1) .......................................................................................................... 26 	
7.3 	Baseline (Visit 2)  ............................................................................................................ 27 	
7.4 	Month 3 (Visit 3)  ............................................................................................................. 28 	
7.5 	Month 6 (Visit 4)  ............................................................................................................. 28 	
7.6 	Month 9 (Visit 5)  ............................................................................................................. 28 	
7.7 	Month 12 (Visit 6)  ........................................................................................................... 29 	
    
ADC -046-INI 
IND #: 119,232  
 
   Page 3 of 55
 7.8 	Month 15 (Visit 7, Open Label)  ......................................................................................  29 	
7.9 	Month 18 (Visit 8, Open Label)  ......................................................................................  30 	
8.0 	EARLY TREATMENT/STUD Y DISCONTINUATION  ........................................................  30 	
8.1	Reasons for Early Discontinuation  ................................................................................. 30 	
9.0 	STUDY -SPECIFIC PROCEDURES  ................................................................................... 31 	
9.1 	Cognitive Evaluations  .................................................................................................... 31 	
9.1.1 	Alzheimer’s Disease Assessment Scale -Cognitive (ADAS -Cog12)  ........................  31 	
9.1.2 	Mini-Mental State Examinations (MMSE)  ...............................................................  31 	
9.1.3 	Memory Composite ( Story Recall a nd Free and Cued Selective Reminding Test)  [ADDRESS_449994] (Wechsler Memory Scale -Revised)  ...................................... [ADDRESS_449995] (Part A and B)  ............................................................................ 32 	
9.2 	Clinical and Functional Evaluations  ............................................................................... 32 	
9.2.1 	Clinical Dementia Rating Scale – Sum of Boxes (CDR -SB) ................................... 32 	
9.2.2 	ADCS -MCI Activities of Daily Living ( ADCS -ADL-MCI) .......................................... 32 	
9.2.3 	Neuropsychiatric Inventory (NPI)  ............................................................................ 33 	
9.2.4 	Modified Hachinski  .................................................................................................. 33 	
9.3 	Research Satisfaction Survey  ........................................................................................  33 	
9.4 	Treatment Blinding Questionnaire  ................................................................................. 33 	
10.0 	STUDY METHODS ............................................................................................................ 33 	
10.1 	Safety Assessments  .................................................................................................... 33 	
10.2 	Physical and Neurological Examination ....................................................................... 34 	
10.3 	Electrocardiogram (ECG)  .............................................................................................  34 	
10.4 	Clinical Laboratory Evaluations  .................................................................................... 34 	
11.0 	BIOMARKER STUDIES .................................................................................................... 34 	
11.1 	CSF ..............................................................................................................................  34 	
11.2 	Blood Collection  ........................................................................................................... 35 	
11.3 	Insulin & Glucose (HgA1c Test)  ................................................................................... 35 	
11.4 	Magnetic Resonance Imaging (MRI)  ........................................................................... 36 	
11.5 	Genetic Samples, Storage and Future Use  ................................................................ . 36 	
12.0 	STATISTICAL PLAN ......................................................................................................... 36 	
12.1 	Power Analyses  ........................................................................................................... 37 	
13.0 	POTENTIAL RISKS .......................................................................................................... 38 	
13.1 	Safety of Intranasal Insulin  ...........................................................................................  38 	
13.2 	Risks associated with use of the POD device ..............................................................  39 	
13.3 	Lumbar Puncture ......................................................................................................... 39 	
13.4 	MRI ..............................................................................................................................  39 	
13.5 	Blood Draw  .................................................................................................................. 40 	
14.0 	PERSONNEL REQUIREMEN TS ......................................................................................  40 	
15.0 	STUDY DRUG  ................................................................................................................... 41 	
15.1 	Humulin® R U- 100 Insulin ............................................................................................  41 	
15.2 	Placebo (Sterile Diluent)  ..............................................................................................  41 	
15.3 	Randomization  ............................................................................................................. 41 	
15.4 	Blinding  ........................................................................................................................  41 	
15.5 	Study Drug Dispensing  ................................................................................................  41 	
15.6 	Intranasal Administrati on .............................................................................................  42 	
15.7 	Compliance  .................................................................................................................. 42 	
15.8 	Dose Adjustments  ........................................................................................................ 42 	
    
ADC -046-INI 
IND #: 119,232  
 
   Page 4 of 55
 15.9 	Breaking the Blind  ........................................................................................................ 42 	
15.10 	Storage  ......................................................................................................................  42 	
15.11 	Drug Accountability  .................................................................................................... 43 	
16.0 	ADVERSE EVENTS  .......................................................................................................... 43 	
16.1 	Definition  ......................................................................................................................  43 	
16.2 	Following Up on AEs .................................................................................................... 43 	
17.0 	SERIOUS ADVERSE EVEN TS (SAE)  .............................................................................. 43 	
17.1 	Definition  ......................................................................................................................  43 	
17.2 	Reporting SAEs  ........................................................................................................... 44 	
18.0 	ETHICS & REGULATORY CONSIDERATIONS  ..............................................................  [ADDRESS_449996] (IRB)  .................................................................................. 44 	
18.3 	Informed Consent & HIPAA Authorization ................................................................... 45 	
18.4 	Participant Confidentiality | HIPAA ............................................................................... 45 	
19.0 	GENETIC RESEARCH & S TORAGE OF GENET IC MATERIAL  ..................................... 46 	
19.1 	Storage of Biospecimen Samples  ................................................................................ 46 	
20.0 	RISKS AND BENEFITS A SSOCIATED WITH THIS STUDY  ........................................... 46 	
20.1 	Potential Benefits of the Proposed Research to Human Subjects  ...............................  46 	
20.2 	Inclusion of Women and Minorities  .............................................................................. 47 	
20.3 	Inclusion of Children as Participants in Research Involving Human Subjects  ............. 47 	
21.0 	STUDY MONITORING & D ATA COLLECTION  ...............................................................  47 	
21.1 	Communication Plan & Site Monitoring  ....................................................................... 48 	
22.0 	DATA AND SAFETY MONI TORING PLAN AND BOAR D ............................................... 48 	
23.0 	PUBLICATION POLICY .................................................................................................... 49 	
24.0 	CLINICAL TRIAL REGISTRATION & SHARING O F FINAL RESEARCH DAT A ........... 49 	
25.0 	TABLE 4: SCHEDULE OF  PROCEDURES AND ASSESSMENTS ................................  50 	
26.0 	LITERATURE CITED  ........................................................................................................ 51 	
    
ADC -046-INI 
IND #: 119,232  
 
   Page 5 of 55
  
STUDY GLOSSARY 
 
3MSE  MODIFIED MINI -MENTAL STATUS EXAM  
AΒ BETA AMYLOID 
AD ALZHEIMER’S DISEASE  
ADAS -COG ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE 
SUBSCALE 
ADCS  ALZHEIMER’S DISEASE COOPERATIVE STUDY  
ADCS -ADL  ALZHEIMER’S DISEASE COOPERATIVE STUDY - ACTIVITIES OF 
DAILY LIVING  
ADEAR ALZHEIMER’S DISEASE EDUCATION AND REFERR AL CENTER  
ADNI  ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE  
AE ADVERSE EVENT  
AMCI  AMNESTIC MILD COGNIT IVE IMPAIRMENT  
ANCOVA  ANALYSIS OF COVARIAN CE 
APOE/APOE4  APOLIPOPROTEIN (APOE ) EPSILON 4 (APOE4) 
ATRI  ALZHEIMER’S THERAPEU TIC RESE ARCH INSTITUTE 
BDNF  BRAIN- DERIVED NEUROTROPHIC  FACTOR  
BID BIS IN DIE (TWICE A DAY)  
BUN BLOOD UREA NITROGEN 
CDR- SB CLINICAL DEMENTIA RA TING – SUM OF BOXES  
CFR CODE OF FEDERAL REGU LATIONS  
CMRGLC CEREBRAL METABOLIC RATE OF GLUCOSE UTILI ZATION  
CNS  CENTRAL NERVOUS SYSTEM  
CPD CONTROLLED PARTICLE DISPERSION 
CPK CREATINE PHOSPHOKINA SE 
CREB CAMP RESPONSE ELEMENT- BINDING PROTEIN  
CRF/E -CRF  CASE REPORT FORM/ELECTRONIC CASE REPORT FORM  
CSF CEREBRAL SPI[INVESTIGATOR_360897] D 
DNA DEOXYRIBONUCLEIC ACI D 
DSMB DATA & SAFETY  MONITORING BOARD  
DSM -IV DIAGNOSTIC AND STATI STICAL MANUAL OF MEN TAL 
DISORDERS, FOURTH ED ITION  
DSRS  DEMENTIA SEVERITY RA TING SCALE  
    
ADC -046-INI 
IND #: 119,[ADDRESS_449997]  HEMATOCRIT  
HCY  HOMOCYSTEINE 
HEENT  HEAD | EARS | EYES |  NOSE | THROAT  
HGB HEMOGLOBIN 
HIPAA HEALTH INSURANCE PORTABILITY AND ACCOUNT ABILITY ACT  
HOMA -IR HOMEOSTATIS MODEL AS SESSMENT OF INSULIN RES ISTANCE  
ICF INFORMED CONSENT FOR M 
ICH INTERNATIONAL CONFER ENCE ON HARMONISATIO N 
IDE INSULIN DEGRADING EN ZYME 
IGF-[ADDRESS_449998]  
ITT INTENT -TO-TREAT 
IU INTERN ATIONAL UNIT  
LDH  LACTATE DEHYDROGENAS E 
LP LUMBAR PUNCTURE  
LTP LONG TERM POTENTIATI ON 
MCV  MEAN CORPUSCULAR VOL UME  
ML MILLILITER  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 7 of 55
 MMA  METHYLMALONIC ACID  
MMSE  MINI MENTAL STATE EX AMINATION 
MPRAGE  MAGNETIZATION PREPAR ED RAPID GRADIENT EC HO 
MR/MRI  MAGNE TIC RESONANCE / MAGN ETIC RESONANCE IMAGI NG 
NBAC NATIONAL BIOETHICS ADVISORY COMMISSION  
NIA NATIONAL INSTITUTE ON AGING  
NIH NATIONAL INSTITUTES OF HEALTH 
NINCDS/ADRDA  NATIONAL INSTITUTE O F NEUROLOGICAL AND C OMMUNICATIVE 
DISEASES AND STROKE / ALZHEIMER'S  DISEASE AND RELATED 
DISORDERS ASSOCIATIO N 
NBDA  N-METHYL – D-ASPARTATE  
NSAID NON- STEROIDAL ANTI -INFLAMMATORY DRUGS  
OHRP  OFFICE FOR HUMAN RES EARCH PROTECTIONS  
PBMC  PERIPHERAL BLOOD MON ONUCLEAR CELL  
PD PROJECT DIRECTOR  
PCP PRIMARY CARE PHYSICI AN 
PET POSITRON EMISSION TO MOGRAPHY  
PHI PROTECTED HEALTH INFORMATION  
PI [INVESTIGATOR_360898]  
T TESLA  
TSH THYROID STIMULATING HORMONE  
U/A URINALYSIS  
WBC  WHITE BLOOD COUNT  
 
 
  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 8 of 55
  
SIGNATURE [CONTACT_115527] #: ADC-046-INI 
IND #: 119,232 
Final Protocol v. 5.0 
05-Dec ember-2016 
 
(SIGNATURES ON FILE AT ATRI) 
 
 
 
 
 
 
 
 
_______________________________________  ___________________ 
Tiffany Chow, M.D.      Date (MM/DD/YYYY) 
Medical Monitor 
Alzheimer’s Therapeutic Research Institute  
 
 
 
_______________________________________  ___________________ 
Suzanne Craft, Ph.D.      Date (MM/DD/YYYY) 
Project Director 
Wake Forest University 
 
 
 
 
_______________________________________  ___________________ 
Paul Aisen, M.D.      Date (MM/DD/YYYY) 
Director 
Coordination & Data Management Center 
Alzheimer’s Therapeutic Research Institute 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 9 of 55
 PROTOCOL SYNOPSIS 
 
TITLE    Therapeutic effects of intranasally- administered insulin  (INI) 
in adults with amnestic mild cognitive impairment (aMCI) or 
mild Alzheimer’s disease (AD)  
PROJECT DIRECTOR  Suzanne Craft, Ph.D. 
STUDY SPONSOR  Nationa l Institute on Aging  
STUDY PHASE     Phase II/III 
INDICATION     Amnestic m ild cognitive impairment (aMCI) or probable mild 
Alzheimer’s disease  (AD) 
AIM OF STUDY  To examine the effects of intranasally -administered insulin 
(INI) on cognition, entorhinal co rtex and hippocampal 
atrophy, and cerebrospi[INVESTIGATOR_360899] (aMCI) or probable mild Alzheimer’s 
disease (AD)   
PRIMARY OBJECTIVE  To test the hypothesis that  12 months of treatment with INI  
(compared to placebo) in adults with aMCI and probable 
mild AD  will improve performance on  a global measure of 
cognition  
SECONDARY OBJECTIVES  1. To test the hypothesis that 12 months of treatment with 
INI (compared to placebo) in adults with aMCI and 
probable  mild AD will improve performance on a 
memory composite (Story Recall and FCSRT ) and daily 
functioning . 
 
2. To test the hypothesis that INI treatment reduces the 
rate of hippocampal and entorhinal atrophy as 
measured by [CONTACT_9268], and to conduct exploratory analyses 
of other brain regions.  
 
3. To test the hypothesis that INI will favorably alter CSF 
Aβ and the CSF Aβ/tau ratio, and will modulate 
inflammatory markers.  
 
4. To examine whether baseline AD biomarker profile, 
APOE- ε4 allele carriage and gender predict treatment 
response. 
 
5. To determine wh ether further improvement occurs after 
18 months of treatment . 
PRIMARY OUTCOME MEASURE  Alzheimer’s Disease Assessment Scale -Cognition  12 
(ADAS- Cog12 ) 
    
ADC -046-INI 
IND #: 119,[ADDRESS_449999]- SB, 
MMSE , ADCS -ADL-MCI, rate of hippocampal and entorhinal 
atrophy, CSF total tau, Aβ40, Aβ42, phospho- tau 181  
STUDY DESIGN   Multi -site, double- blind, placebo -controlled study in 240- 300 
participant s with aMCI or probable mild AD for 12 months, 
followed by a 6 -month open -label period in which all 
participants will receive INI.  
SAMPLE SIZE  • n= 240-300 
• 50% (n=120- 150) assigned to active INI (2 0 IU bid) ; 50% 
(n=120-150) assigned to placebo  
SUMMARY OF KEY ELIGIBILITY  
CRITERIA   • Diagnosis of  aMCI or probable  mild AD according to the  
core clinical criteria updated  in the  NIA and Alzheimer’s 
Association guidelines .   
• Age: 55 to 85  yrs (inclusive)  
• MMSE > 20 at screening  
• Clinical Dementia Rating 0.5 -1 at screening 
• For aMCI only: Logical Memory ≤10 for 16 or more years 
of education, ≤6 for 8 -15 years of education, ≤4 for 0 -7 
years of education ( Delayed Paragraph Recall of 
Wechsler Memory Scale –Revised) . Measured at 
screening  
• Modified Hachinski score ≤ 4 
DRUG DOSAGE & FORMULATION  20 IU Humulin® R U- 100 or matching placebo twice daily 
(bid) for a total of 40 IU daily 
DURATION OF PARTICIPATION  The approximate timeline for this four- year study is 
projected as:  1) approximately six m onths for s tudy startup 
activities  including  FDA and IND submission, site IRB and 
regulatory approval, and training meeting;  2) approximately 
18 months for recruitment; 3 ) 18 months of follow up (last 6 
month s are open label)  
PLACEBO  A matching placebo (sterile diluent) will be used  
ROUTE OF ADMINISTRATION   Intran asal 
PROCEDURES   Physical  and neurological exam, nasal examination,  optional 
lumbar puncture, MRI, ECG, M odified Hachinski, ADAS -
Cog12, CDR -SB, ADCS -ADL-MCI, memory comp osite 
(Story Recall and FCSRT ), Trail-making test , MMSE,  NPI, 
Vitals, Clinical Labs, CSF analysis & banking , Peripheral 
Blood Mononuclear Cell  (PBMC ) isolation  & banking , 
plasma biomarker s and genotypi[INVESTIGATOR_007]. 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450000]. This study will 
examine a novel therapeutic approach using intranasally administered insulin (INI) that has shown promise in s hort-term clinical trials. If successful, information gained from the study has 
the potential to move INI forward rapi[INVESTIGATOR_4782] a therapy for AD. The study will also provide evidence for the mechanisms through which INI may produce benefits by [CONTACT_360929] C SF 
biomarkers and hippocampal/entorhinal atrophy. These results will have considerable clinical and scientific significance, and provide therapeutically -relevant knowledge about insulin’s 
effects on AD pathophysiology.  
 
1.[ADDRESS_450001] the hypothesis that  12 months of treatment with INI  (compared to placebo) in adults with 
aMCI or  probable mild AD  will improve performance on  a global measure of cognition ( ADAS-
Cog12).   
 1.[ADDRESS_450002] the hypothesis that  12 months of treatment  with INI  (compared to placebo) in adults with 
aMCI or probable  mild AD  will improve performance  on a memory composite (Story Recall and 
FCSRT ) and on daily function in adults with aMCI and mild  AD.  
 1.2.[ADDRESS_450003] the hypothesis that INI will favorably alter CSF Aβ and the CSF Aβ/tau ratio, and will  
modulat e inflammatory markers.  
 1.2.[ADDRESS_450004]  
treatment response.   
 1.2.5 Secondary Aim 5  
 
To determine whether further improvement occurs after 18 months  of treatment . 
  
 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 12 of 55
 2.0 BACKGROUND AND SIGNIFICANCE  
 
2.1 Rationale for Insulin  
 
The rationale for the study is derived from growing evidence that insulin carries out multiple 
functions in the  brain, and that insulin d ysregulation may contribute to AD pathogenesis  (Craft 
and Watson 2004) . Insulin receptors are densely  localized in the hippocampus and  in 
entorhinal, frontal, and other cortical areas; they are found primarily in  synapses, where insulin 
signaling modulates synaptogenesis and synaptic remodeling  (Chiu,  Chen et al. 2008 ; Zhao and 
Townsend 2009 ). Insulin facilitates memory at optimal levels, possibly through synaptic effects 
and enhanced hippocampal glucose utilization  (Grillo, Pi[INVESTIGATOR_360900]. 2009 ).  
 The importance of insulin in normal brain function is underscored by [CONTACT_360930], a disorder  characterized in its earliest 
stages by [CONTACT_360931]. Hoyer and colleagues first  identified a 
reduction in insulin receptors and signaling markers in the AD brain  (Frolich, Blum -Degen et al. 
1998). This initial finding has been  confirmed and extended by [CONTACT_127761], who have 
demonstrated reduced CSF insulin in patients with  AD and MCI  (Craft, Peskind et al. 1998 ; Gil-
Bea, Solas et al. 2010), and reduced insulin and IGF- I messaging with increasing AD pathology 
and cholinergic  deficit  (Rivera, Goldin et al. 2005 ). Insulin has a close relationship with β-
amyloid, the toxic peptide produced by [CONTACT_360932]  (Zhao and 
Townsend 2009 ). In AD, insoluble Aβ peptides deposit in brain parenchyma and vasculature. 
Soluble Aβ  species, particularly oligomers of the 42 amino acid specie (Aβ42), have 
synaptotoxic effects, possibly  resulting in synapse loss, which is the earliest structural defect 
observed in AD  (Selkoe 2008 ). Insulin reduces oligomer  formation and  protects against Aβ-
induced synaptotoxicty  and LTP disruption  (Gasparini, Gouras et al. 2001; De Felice, Viei ra et 
al. 2009; Lee, Kuo et al. 2009 ). Interestingly, Aβ also  regulates brain insulin signaling. Soluble 
Aβ binds to the insulin receptor and disrupts insulin signaling and LTP  induction in mouse 
hippocampal  slice preparations ( Townsend, Mehta et al. 2007 ). These effects could be 
prevented by [CONTACT_360933] Aβ exposure. Insulin pre -treatment al so 
prevented synthetic soluble Aβ oligomers from  downregulating plasma membrane insulin 
receptors and reducing dendritic spi[INVESTIGATOR_360901]  (De Felice, Vieira et al. 
2009). Insulin may also modulate Aβ degradation by [CONTACT_360934] (IDE), a metalloprotease that catabolizes insulin  (Zhao, Teter et al. 2004 ). Collectively, 
these findings suggest that soluble Aβ may induce central nervous system ( CNS ) insulin 
resistance and synapse loss, and that treatment with insulin may prevent  these pathological 
processes . 
 
A role for in sulin has also been suggested for other AD -related mechanisms. Insulin inhibits  
phosphorylation of tau, through its regulation of glycogen synthase kinase 3β, a downstream 
target in the  insulin  signaling pathway  (Hong and Lee 1997 ). Insulin dysregulation is also 
associated with oxidative stress, inflammation, and  impaired neurogenesis  (Craft and Watson 
2004). Thus, insulin has been implicated in numerous processes related to AD  pathophysiology, 
suggesting that correction of insuli n dysregulation may be a therapeutic strategy  with 
considerable clinical and scientific significance.  
 2.2 Insulin as a Therapeutic Agent  
 
The study use s insulin as a therapeutic agent and  intranasal administration focusing on nose to 
brain transport as a mode  of delivery. As reviewed above, insulin has pleiotropic effects on 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450005] to the majority of therapeutic approaches that focus on  
narrow ly defined mechanisms such as acetylcholine modulation or amyloid accumulation. 
Restoring normal  brain insulin levels in persons with AD may improve cognition and AD 
pathologic processes. Such an approach  is possible with an intranasal administration technique.  
 
2.2.1 Intranasal Pathways to the CNS  
  
Olfactory sensory neurons are directly exposed to the external  environment in the upper nasal 
cavity while their axons extend through the cribriform plate to the olfactory bulb.  Following 
intranasal administration, d rugs can be directly transp orted to the CNS, by[CONTACT_360935].  Several extraneuronal and intraneuronal pathways from the nasal cavity to the CNS 
are possible. The  extraneuronal pathways appear to rely on bulk flow transport through 
perineural channe ls to the brain or CSF.  In recent studies, labeled INI or a closely related 
peptide, insulin- like growth factor- I (IGF -I), were administered  to rodents  (Thorne, Pronk  et al. 
2004; Francis, Martinez et al. 2008 ). Within [ADDRESS_450006] was identified with quick access to the CSF after absorption into 
the submucosa along the olfactory nerve and cribriform  plate ( Born, L ange et al. 2002 ; Frey 
2002; Thorne, Pronk et al. 2004 ). These extracellular pathways provide direct access to the 
CNS within minutes of intranasal  admini stration. Additionally, an intraneuronal pathway delivers 
drugs to the CNS hours or days later (Broadwell and Balin 1985 ; Shipley 1985; Baker and 
Spencer 1986 ; Balin, Broadwell et al. 1986). Viruses and microorganisms  (Fairbrother and Hurst 
1930; Faber 1938 ; Bodian and Howe 1941 ), amino acids  (Weiss and Holland 1967 ), and 
proteins  (Kristensson and Olsson 1971; Shipley 1985; Thorne, Emory et al. 1995 ) can also 
enter the CNS via nasal routes. In particular, substances with lower molecular weights are more likely to be transported to the CNS along intranasal pathways  (Sakane, Akizuki et al. 1995 ). 
Insulin’s molecular weight of about 5800 g/mol makes it a good candidate for intranasal delivery.  
Animal studies show labeled uptake to hippocampus and  rostral and caudal cortex following INI  
administration ( Francis, Martinez et al. 2008) . In a murine diabetes model, INI reduced brain 
atrophy, while increasing s ynaptic markers and activation of Akt, CREB, and [COMPANY_004]3β. Memory 
enhancement was also observed on Water Maze and radial arm  tasks  (Francis, Martinez et al. 
2008). H uman functional and cognitive studies of INI also support insulin’s transport to the CNS. 
INI treatment  increases CSF insulin levels and induces changes in auditory -evoked brain 
potentials compared to placebo ( Kern, Born et al. 1999 ). INI improves verbal memory acutely in 
persons with AD  and aMCI without affecting  plasma insulin or glucose levels at the dose 
included in the study  (Reger, Watson et al. 2006 ). Regarding chronic effects,  several studies 
reported that 2 months of daily insulin administration (160 IU/day) significantly improves verbal  
memory in y oung healthy adults ( Benedict, Hallschmid et al. 2004 ; Stockhorst, de Fries et al. 
2004; Benedict, Kern et al. 2008 ; Hallschmid, Benedict et al. 2008 ; Stockhorst, de Fries et al. 
Submitted for publication ). Finally, Section 3.[ADDRESS_450007] em Devi ces 
 
The Precision Olfactory Delivery (POD) Device developed b y Impel NeuroP harma (Seattle, WA) 
will be provided  to study participants. Typi[INVESTIGATOR_360902] 20% of the lower nasal ca vity.  D ue to gra vity and insufficient 
airflow, approximately 90% of the droplets end  up in the stomach. The POD device  deliver s a 
substance throughout the nasal cavity to the olfactory region and paranasal sinuses, thereby 
    
[CONTACT_360936] -046-INI 
IND #: 119,232  
 
   Page 14 of 55
 maximizing access to nose -to-brain channels.   
 
The POD device reliably delivers drug to the upper nasal cavity  by [CONTACT_18120] a commercially 
available metered dose inhaler canister, an actuator containing a diffuser and a nasal tip.   The 
canister contains liquid hydrofluoralkane (HFA), a propellant used whose use in metered dose 
inhalers was re quired by [CONTACT_34033] 2012 as a replacement to chlorofluorocarbons. HFA 
propels the study drug to the nasal cavity.   The HFA travels through the POD actuator body and 
enters the POD tip, where it mixes with the study drug formulation.  The study drug formulation and HFA are then sprayed from the device.  
 A drug -device compatibility and functionality verification of the Impel NeuroPharma clinical 
Precision Olfactory Delivery device and the Novolog
® insulin formulation was conducted (Impe l 
NeuroPharma, 2015) t o identify  the optimal dose volume of Novolog® insulin required to 
achieve the target dose and confirm that the POD device consistently delivered the desired 
amount of both insulin and placebo. A qualitative assessment using an anatomically 
representative human nasal cavity model (derived from Liu, Johnson et al, 2008) confirmed that 
the insulin deposition was concentrated in the upper nasal cavity region.  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 15 of 55
 
3.0 PRELIMINARY STUDY 
 
A preliminary study  using the Kurve ViaNaseTM device – a device similar to the Impel POD 
device in terms of drug delivery action -- examined the impact of 4-month INI administration (10 
or 20 IU bid vs. placebo) on the primary outcome measures of delayed story recall and the Dementia Severity Rating Scale (DSRS) as well as on measures of global cognition and 
function used in traditional AD clinical  trials. In a subset of partici pants, effects on CSF AD 
biomarkers (Aβ42 and tau/Aβ42 ratio),  and on cerebral metabolic rate of glucose utilization 
(CMRglc) assessed by F 18FDG PET  were also examined (Craft, Baker et al. 2012 ).  Given the 
similar drug delivery action  and equivalent dosing between the Kurve ViaNase
TM and Impel 
NeuroPharma POD devices, the preliminary study is applicable to the Impel POD  device used in 
this study.  
 3.1 Participants  
 
A total o f 111 older adults were randomized in the study (Fig. 1). Data from 104 participants 
were analyzed.  
 Sample composition (aMCI, n=64; AD with MMSE  >15, 
n=40), size, and diagnostic criteria were  based on a 
previous study  (Reger, Watson et al. 2008 ). Forty  participants (15 
placebo, 13 low dose insulin and 12 high dose insulin) comp leted the PET sub -study, and 23 participants (n=8 
placebo and 15 insulin) completed the LP sub - study. 
Diagnoses were determined by [CONTACT_360937]. Participants, caregivers, and 
all personnel involved in data  collection 
were blinded to treatment assignment. 
Groups did not differ in education, body mass i ndex, MMSE,  gender, diagnosis, 
cholinesterase inhibitor  treatment, or 
apolipoprotein E (APOE) ε4 allele  
carriage (Table 1 ).  
 Table 1 | Participant  Characteristics  
 
 
Participants in the high dose  insulin group were younger than pla cebo -assigned  participants 
(p=0.02), whereas no differences were  observed between placebo and low dose insulin  groups. 
Age was included as a covariate in all  analyses.  Figure 1 | Trial Enrollment Flow  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 16 of 55
 3.2 Procedures  
 
Participants were  randomized to receive 10 IU INI bid for a total daily  dose of 20 IU INI (n=36), 
20 IU INI bid for a total dose  of 40 IU (n=38) or placebo (saline bid, n=30) for 4 months. 
Participants were stratified by [CONTACT_291292]- ε4 carriage. Saline or insulin (Novolin R, Novo) was  
administered after breakfast and dinner with ViaNase™, an intranasal delivery system  (Craft, 
Baker et al. 2012 ). Parallel versions  of the cognitive protocol were administered at  baseline, and 
months 2 and 4 of treatment. Co -primary outcome measures were  delayed story recall and the 
DSRS  which had previously demonstrated  beneficial effects of insulin  (Reger, Watson et al. 
2008). Secondary measures included the AD  Assessment Scale for Cognition (ADAS -Cog) 
(Reger, Watson et al. 2008 ), a test comprised of  measures of memory, orientation, and  
language, with higher scores reflecting  impairment ranging from 0 (best) to 70  (worst), and the 
ADCS -Activities of Daily Living scale (ADCS -ADL)  (Galasko, Bennett et al. 1997 ). Baseline and 
post-treatment fasting CSF was analyzed for Aβ42 and tau with multi -parameter bead- based 
immunoassay INNO -BIA AlzBio3 (Innogenetics NV). Resting PET images w ere obtained using 
a GE Advance PET scanner (GE Medical Systems, Milwaukee, WI) using a p reviously 
described protocol  (Baker, Cross et al. 2011 ). 
 
3.3 Safety and Compliance  
 
Support persons supervised participants’ intranasal administration. Blood  glucose wa s 
measured daily for the first week and then weekly; no group changes were observed over the  
course of the s tudy (Craft, Baker et al. 2012 ). Compliance was monitored by [CONTACT_360938]. Safety d ata were reviewed semi -annually by a Data and Safety Monitoring Board. Adverse 
event reporting followed standard guidelines.  
 
3.4 Statistical Analyses  
 
For the inten t-to-treat (ITT) sample, co -primary (delayed story recall  and DSRS)  and secondary 
(ADAS -Cog and ADAS -ADL) scores were log transformed. Scores were first subjected to  mixed 
model repeated ANCOVA including all treatment groups (placebo, low dos e insulin or h igh dose 
insulin) as the between subjects factor, and time (baseline, month 2, month 4) as the repeated 
factor using the SAS  v9.2 General Linear Models procedure. After a significant (p<0.05) time by 
[CONTACT_360939] a different pattern of change, each of the two insulin 
groups was compared separately with the placebo group using repeated measures ANCOVAs. 
Effect sizes (Cohen’s f 2) were calculated for all significant  effects. Age was included as a 
covariate in all analyses. Diagnosis ( aMCI or AD), gender, APOE- ε4 carriage  status (yes or no), 
baseline 3MSE score,  and years of education we re also included as covariates. Non-significant  
covariates were dropped from the model. Significant relationships with covariates were explored  
with Pea rson correlation (continuous variables) or follow -up ANOVAs (class variables). Missing 
values were treated with multiple imputation  (Rubin 1987 ). For exploratory CSF biomarker 
analyses, because only a subset of  participants elected to undergo LP and no differences were 
observed between the two insulin dose arms,  the groups were combined into a single  insulin -
treated group to maximize power. Biomarkers were analyzed with  the repeated ANCOVA 
strategy described above and , due to the small sample size, exploratory Spearman correlations 
were conducted to examine relationships among changes in biomarkers an d outcome 
measures.  Only study completers underwent post -treatment FDG -PET. Pre  and post  treatment 
scans were co -registered  within subject and anatomically standardized to Talairach and 
Tournoux stereotactic coordinates ( Talairach and Tournoux 1988 ; Minoshima, Koeppe et al. 
1994). Pi[INVESTIGATOR_360903]  (Minoshima, Frey et al. 1995 ). Interval 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 17 of 55
 regional CMRglc changes within groups were assessed  using voxel -wise one -sample t statistics 
(pre-/post -treatment pair) and probability integral con version to z scores ( Worsley, Evans et al. 
1992). Interval changes in regional CMRglc were then compared between 1) low insulin vs. 
placebo groups,  and 2) high insulin vs. placebo groups. Based on the number of voxels and 
smoothness of the statistical map, a Type I error rate was controlled at 0.05 to account for 
multiple comparisons ( Worsley, Evans et al. 1992 ). The resulting statistical maps  were 
visualized in three -dimensional stereotactic surface projections.  
 
3.5 Results: Cognitive and Functional Outcome Measures  
 
The three groups di d not differ at baseline on any outcome measure; change from baseline is 
represented in figures for ease of interpretation. A significant  overall treatment group by [CONTACT_360940] (p=0.005).  Compared to 
placebo, the low dose group had imp roved delayed recall (Fig. 2A; treatment by [CONTACT_5586] p=0.02,  
Cohen’s f 2=0.36), whereas no effect was observed for the high dose group . Exploratory post -
hoc analyses were then conducted to more closely examine the relationship of insulin dose to 
story recall, as this was a primary goal of this pi[INVESTIGATOR_29833]. Given findings that delayed recall 
may not be a sensitive measure for AD  subjects due to increased variability and floor effects  
(Sano, Raman et al. 2011) we constructed a total story recall score (immediate and delayed), 
which  showed improvement for the high -dose group (time by [CONTACT_9866] p<0.05, 
mean log total story recall change score with SEM = -.15(.1) for placebo vs.12 (.09) for the high 
dose group). A significant overall treatment by [CONTACT_360941], the DSRS (p=0.008). Compared with placebo, DSRS scores were preserved for both low and high dose groups ( Fig.2B; trea tment by [CONTACT_360942]=0.01 and 0.01, 
Cohen’s f 2=0.38 and 0.41). For  secondary measures, significant ef fects  were observed for the 
ADAS- Cog (overall treatment by [CONTACT_6491]  p=0.004). Both low and high insulin groups had 
less decline in cognition compared with placebo (Fig. 2C; treatment by [CONTACT_360942]=0.04 and 
p=0.002,  Cohen’s f2=0.27 and .40). Treatment  effects on the ADAS- Cog interacted with age; for 
the high dose insulin group,  greater improvement (lowered score) tended to be associated with 
younger  age (r=.31, p=0.06). For the ADCS -ADL, no overall effects of treatment on daily 
function were observed.  However, a significant interaction with diagnosis was observed for this 
measure (overall treatment by [CONTACT_360943] p=0.02). Participants with AD receiving either dose of insulin had preserved function compared with placebo -assigned 
participants with AD who showed slight decline, whereas participants with aMCI showed no 
change regardless of treatment assignment (interactions for the participants with AD in low and 
high dose groups compared with placebo, ps=0.01 and 0.02, Cohen’s f=0.45 and 0.43; Fig. 2D). 
Adjustment for APOE -ε4 status, baseline MMSE score, cholinesterase inhibitor treatment,  
gender, and education did not affect the pattern of any result. 
 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 18 of 55
 Figure 2 | Change (Month 4 -baseline) in log scores for (A) delay ed story recall, (B) DSRS, (C) 
ADAS -Cog and (D) ADCS -ADL.  
 
 
3.6 Results: AD Biomarkers   
 
CSF Aβ42, Aβ40 and tau did not change for the placebo or insulin -treated groups as a whole. In 
exploratory analyses, however, for insulin -treated participants, increased CSF Aβ42  
concentrations were associated with improved delayed story recall and ADCS- ADL score s, 
whereas decreased  Aβ42 was associated with worse performance (Spearman rhos=.59, p=0.02 
and .60, p=0.02). Similarly,  decreased tau/Aβ42 ratios over the 4- month study period correlated 
with improved delayed story recall and  better daily function on both ADAS -ADL and DSRS for 
insulin -treated participants (Spearman rhos= -.52, p=0.05, -.50, p=0.07, and .53, p=0.05). No 
significant correlations were observed for the placebo group.  
 
3.7 Results: FDG -PET CMRglc  
 
Compared with placebo -assigned participants, the lower dose insulin group  showed reduced 
progression of hypometabolism in bilateral frontal, right temporal, bilateral occipi[INVESTIGATOR_307], and right  
precuneus  and cuneus regions  over the 4 -month treatment  period (Fig. 3 and Table 2). The 
higher  dose insulin group showed even greater  treatment effects  (higher Z scores)  indicating 
less hypometabolism  progression in most  regions and in left parietal cortex.  
 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 19 of 55
 Figure 3 | Areas of hypometabolism at baseline (scan 1) and month 4 (scan 2), along with changes 
in hypometabolism (time 2 -time 1) within each group and differences in change between placebo 
and low or high insulin groups (nasal insulin -placebo).  Hotter floors indicate areas of greater 
hypometabolism from time 1 to time 2, and from placebo to insulin groups.  
 
 
Table 2 | Z scores and stereotactic coordinates for areas of reduced progression for low and high 
does insulin groups comp ared to placebo 
 
 
3.8 Safety and Compliance  
 
No treatment -related serious adverse events ( SAEs ) occurred during the study; most adverse 
events ( AEs) were  minor, such as mild rhinitis. AEs with an occurrence of >5% in any group are 
listed in Table 3. The total  AE mean was higher for the low dose group compared with placeb o 
(low dose mean total AEs with standard  error=1.44± 0.20, placebo =0.80± .22, p=0.04), with a 
similar trend for the high dose and placebo group  comparison (high dose mean total AEs 
=1.21 ±0.16, placebo =0.80 ±.22, p=0.10). Mean compliance (number of completed doses) 
ranged from 95 -97% and did not  differ across groups.  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 20 of 55
 Table 3 | Total number of adverse events and per cent of sample for all events occurring for at 
least 5% of t he participants in any treatment group.  
 
 
3.[ADDRESS_450008] that adults with aMCI or AD may benefit  from INI treatment. Compared 
with placebo,  the lower dose of insul in improved delayed memory, and both insulin doses 
preserved caregiver -rated ability to  carry out daily functions. General cognition as assessed  with 
the ADAS -Cog, the primary outcome measure for the  current  trial, was also preserved by [CONTACT_360944]. In  exploratory analyses, changes in CSF Aβ42 and tau/Aβ42  ratios were  
associated with cognitive and functional  changes for insulin -treated participants. Placebo -
assigned  participants showed decreased CMRglc values in frontal, temporal, and parietal 
cortices as well as  precuneus  and cuneus over th e 4-month period, whereas insulin -treated 
participants showed no decline. The longstanding FDG PET finding of posterior cingulate , 
precuneus  and cuneus hypometabolism in AD has been  hypothesized to be due to functional  
disconnection of the hippocampal formation, so enhanced metabolism  and memory with INI 
may reflect enhanced hippocampal input to this region. Similarly there are strong  connections 
between the posterior cingulate, precuneus , cuneus and prefrontal and supe rior temporal cortex  
(Cavanna and Trimble 2006 ), which may also be affected by [CONTACT_360945]. Finally, no treatment -related 
SAEs occurred. These promising results provide a strong rationale for the longer, larger, multi -
site trial proposed in this application. 
 
4.0 STUDY DESIGN RATIONALE  
 
4.1 Rationale for Population Selection  
 
Similar  to previous pi[INVESTIGATOR_360904]  (Craft, Baker et al. 2012 ), participants 
with aMCI or probable mild AD  will be enrol led in the current study .  The rationale for this 
approach is based on the lack of clear clinical or neuropathologic borders between the two conditions, such that recent reviews on trial design have suggested a combined group  approach  
(Aisen, Andrieu et al. 2011). E nrollment will not be restricted to biomarker -positive patients .  The 
trial will collect CSF biomarkers and MRI measures of atrophy.  T hus, secondary analy ses will 
explore the relationship of biomarkers to treatment response. Inclusionary criteria parallel the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI ) criteria , which will allow compar isons of 
imaging and biomarker data to the large ADNI cohort.  
 4.2 Rationale for  Dosage Selection  
  
The dosage selected (20 IU INI bid for a total of 40 IU INI daily) showed greater effect  sizes for 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 21 of 55
 the ADAS -Cog and greater ability to preserve cerebral glucose metabolism with PET with a 
good safety profile than did a lower 10 IU dose ( Craft, Baker et al. 2012 ). Although the  delayed 
story recall did not change with 20 IU INI bid, the trial used different inclusion criteria than the 
current study (MMSE ≥15 compared with MMSE ≥ 20) and did not sum immediate and delayed 
story recall. Exploratory analyses were conducted comparing the 20 IU bid dose with placebo in 
only participants with MMSE ≥ 20, and summed immediate and delayed recall. A significant time 
by [CONTACT_360946] (p<0.05), reflecting improved performance for the 20 IU 
bid INI-treated group and decline for the placebo group (mean log ical memory  total story recall 
change score with standard error = .15 (.1) for p lacebo vs .12 (.09) for the 20 bid IU INI group)  
(Craft, Baker et al. 2012). 
 
4.[ADDRESS_450009] shown that the ADAS -Cog changes reliably over 12 months in 
both aMCI and AD  groups ; these results served as the basis for the study power analyses . A 
version of the ADAS -Cog that includes a delayed list recall will be used as primary outcome 
measure. Altho ugh adding delayed recall to ADAS -Cog does not improve ability to  detect 
change over time in AD patients because of increased variability, it does provide added sensitivity to detect change in aMCI  (Petersen, Aisen et al. 2010). ADAS- Cog12 will be 
administered at [ADDRESS_450010] demonstrated significant decline over a 12-month period for aMCI and mild AD  (Petersen, Aise n et al. 2010 ).  In particular, a memory 
composite  that combines  immediate and delayed story recall scores and the Free and Cued 
Selective Reminding Test  (FCSRT ) will be used. The two measures will be combined with equal 
weighting in order to  be sensitive to improved memory for both aMCI and AD. With respect to 
MRI measures, both hippocampal and entorhinal volume changes occurred over 12 months in 
ADNI  (Petersen, Aisen et al. 2010 ). 
 
4.4 Rationale for Length and Design of Trial  
 
In the pi[INVESTIGATOR_799] (Craft, Baker et al. 2012 ), beneficial effects of insulin on cognition, function and 
cerebral glucose metabolism were detected in a [ADDRESS_450011] 
clear changes in memory and imaging endpoints for both aMCI  and AD  groups . The additional 
6–month, open -label extension used in this semi -crossover design may incentivize participants 
to enroll and remain in the trial, and also provide added power for safety analyses  (Jarjoura 
2003) . Exploratory efficacy analyses may also provide useful informat ion, although these results 
will need to be interpreted with caution in light of their unblinded status.  
 4.5 Rationale for Magnetic Resonance Imaging  
 Recent data from ADNI demonstrate that structural MRI can be a credible predictor of future cognitive and fu nctional decline, and it is sensitive to volume reductions over a 12 -month period  
(Vemuri, Wiste et al. 2009) . Jack , et al, examined the role of structural MRI as an endpoint for 
disease progression in therapeutic trials for AD and reported that multi -site consistency is 
feasible  (Jack, Slomkowski et al. 2003) . They also report hippocampal atrophy as one of the 
most reliable correlates of AD progression, such that mitigation of progression would be detectable over a year, given adequate power. Recent studies have also shown that entorhinal cortex has the greatest atrophy rate o ver a 12 -month period compared with other regions  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 22 of 55
 (Holland, Brewer et al. 2009 ). Given this finding, we will evaluate INI effects on both 
hippocampal and entorhinal volumes as our primary MRI outcome measures. However, we will 
also conduct exploratory analyses on other regions such as the precuneus  and cuneus region s 
that ha ve shown INI effects with FDG PET in a previous study (Craft, Baker et al. 2012) .  
 Each site’s scanner will have an identifying number, which will be appended to the image  
header of all MRI data. Each scanner will be subjected to a qualifying process tha t includes an 
evaluation for excessive vibration or other image artifact revealed through submitted MR images obtained through a standard protocol of an American College of Radiology phantom. In addition, 3D T1 MPRAGE or IR -FSPGR images of a human brain ob tained through a standardized 
imaging protocol of a volunteer at each site will be submitted for automated segmentation  and 
the resulting segmentations will be examined centrally for anatomical accuracy.  Once the 
phantom and volunteer scan pass quality control , the scanner will be considered certified for the 
INI study. Because longitudinal analysis of brain volumetry will be used in this study, sites will 
be required to use the same scanner for both scans of a particular participant . Each site will be 
required to procure a clinical read of each participant ’s MRI data by a board  certified radiologist. 
In addition, the image- derived inclusion and  exclusion criteria will be evaluated centrally. All 
imaging data will be de- identified  through a numerical coding system.  
 
4.[ADDRESS_450012] es obtained in this study will be banked so 
that other putative biomarkers (such as CSF insulin, isoprostane 8,12 -iso-iPF2alpha -VI) may be 
measured by [CONTACT_360947]. These 
putative biomarkers  are among the leading candidates for AD biomarker development (Turner 
2003; Grossman, Farmer et al. 2005 ).  For example, Gilman et al , report a highly significant (p < 
0.001) effect of Aβ immunization (with AN1792) on CSF tau with a total sample size of only 21 
(N = 11 antibody responders and 10 placebo control participants ; Gilman, Koller et al. 2005 ).  
 
Several previous studies suggest that response to insulin may differ according to APOE 
genotype. In dose response studies that acutely elevated insulin through intravenous or intranasal administration, the gre atest cognitive benefit was observed for adults with AD who  
were not ε4 carriers  (Reger, Watson et al. 2008 ). The current  study will examine ε4 carriage as 
a treatment response predictor.   
 Although Alzheimer's disease (AD) is a degenerative brain disorder, it may also affect peripheral 
tissue such as peripheral blood mononuclear cells (PBMCs). It has been suggested that PBMC -
associated biomarkers may provide insights into the pathogenesis of AD and be used to monitor 
disease diagnosis and progression  (Maes, Schipper et al. 2009 ). Thus biochemical analysis of 
the effects of intranasal insulin on PBMCs may provide some insights into therapeutic mechanisms. In addition, we will be able to compare treatment -related b iomarker profiles in 
CSF and PBMCs.  
 5.[ADDRESS_450013] of a multisite, randomized, double -blind trial comparing the effects of INI 
(20 IU bid for total daily dose of 40 IU) and placebo for 12 months, followed by a 6 -month open -
label pe riod in which all participants will receive INI. Participants with aMCI or mild AD (n=2 40-
    
ADC -046-INI 
IND #: 119,232  
 
   Page 23 of 55
 300) will be enrolled. The primary outcome measure will consist of the ADAS -Cog12. Secondary 
measures will include a memory composite, an executive function test, CDR  Sum of Boxes  
(CDR- SB), and the ADCS -ADL-MCI. The ADAS -Cog12 will be administered at 3 month intervals 
to optimize imputation of missing data. Other cognitive  and functional measures will be 
administered at 6 month intervals. MRI measures of entorhinal cor tex and hippocampal atrophy 
will be obtained at screening  and 12 months. CSF and plasma biomarkers , as well as PBMCs 
and APOE- ε4 allele carriage  will also be assessed . The trial will be conducted in collaboration 
with the Alzheimer Therapeutic Research Institute (ATRI ).   
 
5.[ADDRESS_450014] to enroll no more than 50% of participants w ith probable mild  AD and no more than 
60% participants with aMCI diagnosis. To determine eligibility , all participants will undergo 
cognitive assessment, physical and neurological examinat ion, ECG, clinical/safety laboratory 
assessment , and interview s of the participant and study partner .  
 5.[ADDRESS_450015] that the 
majority of sites are affiliated with NIH- funded Alzheimer’s Disease Centers  and all sites are 
affiliated with reknowned Alzheimer’s programs ; thus all sites are staffed by [CONTACT_360948].  
 
Participants with a MCI or probable mild AD will be diagnosed accord ing to core clinical criteria  
updated in the NIA and Alzheimer’s Association . 
 Diagnosis of aMCI requires:  
a) Evidence of a decline in epi[INVESTIGATOR_10682]  
b) General preservation of independence i n functional abilities  
c) Absence of dementia  
 
Biomarker evidence cons istent with AD will not be required for entry for either aMCI or probable 
mild AD, given that knowledge in this area is evolving. Also, recent evidence indicates that 
requiring an AD -positive biomarker does not uniformly improve the efficiency of clinical trials  
(Schneider, Kennedy et al. 2010 ).  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 24 of 55
 5.3 Inclusion Criteria  
 
The following inclusion criteria * will be used:  
1. Age 55 to 85 ( inclusive)   
2. Fluent in English or Spanish  
3. Diagnosis of aMCI or probable mild AD according to the core clinical criteria outlined in 
the NIA and Alzheimer’s Association Guidelines.  
4. MMSE ≥ [ADDRESS_450016] 0.5 -1 (inclusive)  at screening  
6. For aMCI group only: Logical Memory ≤10 for 16 or more years of education, ≤6 for 8-15 
years of education, ≤4 for 0 -7 years of education . Scores measured at screening on  
Delayed Paragraph Recall from the Wechsler Memory Scale –Revised  
7. Modified Hachinski score  ≤ [ADDRESS_450017] with the participant > 
2 days/week (minimum of 10 hrs a week)  
9. A study partner able to participate in study drug administration or able to assure that 
another person (such a family member or friend or other) will be able to assist the participant in the study drug administration 
10. Stable medical condition for [ADDRESS_450018] be judged to 
be not clinically  significant by [CONTACT_093]   
15. Visual and auditory acuity adequate for neuropsychological testing  
 
*Exceptions to these criteria may be considered on a case -by-case basis at the discretion of the 
Project Director . 
 5.4 Exclusion Criteria  
 
The following  exclusion criteria * will be used:  
1. A diagnosis of dementia other than probable AD 
2. Probable AD with Down syndrome  
3. History of a clinically significant stroke  
4. Current evidence or history in past two years of epi[INVESTIGATOR_002], focal brain lesion, head injury 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 25 of 55
 with lo ss of consciousness or DSM IV criteria for any major psychiatric disorder 
including psychosis, major depression, bipolar disorder, alcohol or substance abuse  
5. Sensory impairment that would preclude the participant  from participating in or 
cooperating with the protocol  
6. Diabetes (type I or type II)  requiring pharmacologic treatment (including both insulin 
dependent and non- insulin dependent diabetes mellitus)  
7. Current or past use of insulin or any other anti -diabetic medication  within  one (1) year of 
Screening  visit.. 
8. Evidence of any significant clinical disorder or laboratory finding that renders the 
participant unsuitable for receiving an investigational drug including clinically significant 
or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, 
endocrine, metabolic, renal or other systemic disease or laboratory abnormality  
9. Active neoplastic disease, history of cancer  within five years prior to screening (history  of  
stable prost ate cancer or non- melanoma skin cancers are not exclusionary ) 
10. History of seizure within past five years  
11. Pregnancy or possible pregnancy . Participant is not pregnant, lactating, or of 
childbearing potential (i.e. women must be two years post -menopausal or surgically 
sterile)  
12. For participants undergoing  optional lumbar puncture, contraindications to LP : prior 
lumbosacral spi[INVESTIGATOR_79477], severe degenerative joint disease or deformity of  the spi[INVESTIGATOR_050], 
platelets <100,000 or history of a bleeding disorder  
13. For participants undergoing optional lumbar puncture, u se of anticoagulants warfarin 
(Coumadin) and dabigatran (Pradaxa)  
14. Contraindications for MRI (claustrophobia, craniofacial metal implants of any kind, 
pacemakers)  
15. Residence in a skilled nursing facility at screening  
16. Use of an investigational agent within two months of  screening visit  
17. Regular use of narcotics, anticonvulsants, medications with significant anticholinergic 
activity, antiparkinsonian medications, or any other exclusionary medications  
 
*Exceptions to these criteria may be considered on a case -by-case basis at the discretion of the 
Project Director.  
 5.5 Recrui tment and Retention Strategies  
 Recruitment will occur through a variety of mechanisms. The trial design includes a 6 -month, 
open- label extension period in which all participants will receive active drug, w hich will facilitate 
recruitment and retention. Recruitment efforts will also be overseen by [CONTACT_5081] . 
The Coordinating Center  has developed a coordinated recruitment plan to ensure that 
enrollment occurs in a timely fashion.  The overall goals of the plan are to raise awareness of 
this trial among targeted  populations to ensure adequate enrollment. The Coordinating Center  
partners with NIA and coordinates with its ADEAR Center to leverage existing resources. The Coordinating Center  will overs ee the development of  materials specific to the INI  trial for use by 
[CONTACT_30107], provide ongoing recruitment assistance and support, and develop tracking procedures 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 26 of 55
 to monitor effectiveness of recruitment efforts. The recruitment plan for the INI trial will  include 
both the utilization of participant s existing at clinical trial centers and the recruitment of 
additional populations by [CONTACT_360949].  
 
6.0 STUDY TIMELINE   
 
The approximate timeline for this four -year study is projected as follows:  1) approximately six 
months for study startup activities including  FDA/IND submission, site IRB and regulatory 
approval s and the Investigator training meeting; 2) recruitment will last for approximately 18 
months ( for a total of 2 40-300 participants across  about 30  sites); and 3)  18 months of follow up  
(last 6 month s are open label)  
 
7.0 DESCRIPTION OF STUDY VISITS 
 
The “ Schedule of Study Procedures and Assessments” in Table 4 (section 21.0 ) provides an 
overview  of study visit activities.  The p rimary outcome measure  (ADAS- Cog12 ) will be 
measured at Baseline and all subsequent visits at three month intervals to optimize imputation 
of missing data. Secondary outcome measures , plasma  biomarkers, and PBMCs  will be 
measured every six months : Baseline  (with the exception of MMS E and CDR  conducted at  
Screening) , Month 6, Month [ADDRESS_450019] a diagnosis of aMCI or probable mild AD and will be known to meet as many of the 
inclusion/exclusion criteria as possible. Potential participants and study partners will not be considered study participants until they sign the consent form.  
 
7.2 Screening (Visit 1)  
 The purpose of this vis it is to determine study eligibility  and may be conducted over multiple 
days .  Potential participants and their study partners must sign an informed consent form  and 
HIPAA Authorization prior to administration of any study- related procedures. After consent  is 
obtained, participant s will be given the MMSE , the CDR and Logical  Memory  (Delayed 
Paragraph Recall  from the Wechsler Memory Scale –Revised ) to determine study eligibility.  
 In addition,  information regarding demographics, concurrent medications, medical history and 
adverse events will be gathered from the participant and study partner. Vital signs , height and 
weight  will be measured.  A brief physical and neurological examination  (which include a nasal 
examination) , Modified Hachinski scale and a standar d 12- lead resting ECG will be performed. 
The ECG report will be reviewed, signed, and dated by [CONTACT_125078] a medically qualified 
staff member as delegated by [CONTACT_079]. Those with clinically significant ECG 
findings will be referre d for follow -up as deemed appropriate by [CONTACT_093].  
 Blood will be drawn and a urine sample obtained for routine clinical laboratory evaluations.  If 
values are  outside of  the laboratory’s normal range and determined  clinically significant  by [CONTACT_1275] , lab tests may need to be repeated and may be considered exclusionary for 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 27 of 55
 participation in the study. Blood samples will also be collected for ApoE ge notypi[INVESTIGATOR_360905].   
 
A screening MRI scan will be conducted for p articipants who met eligibility criteria (as 
determined by [CONTACT_6962] ). A local clinical read of the MRI will be reviewed by [CONTACT_360950] (or appropriately delegated staff member) for eligibility. If the participant continues to meet all inclusion  and exclusion criteria and no safety concerns are identified from 
the MRI, the participant can proceed to the baseline visit after approval  by a clinical monitor.  
 Prior to randomization , the Project Director must approve any exceptions or question s regarding 
possible exclusionary medications, medical conditions, or laboratory tests.  Re- screen is 
allowed, should the original screen be a failure.  The re -screen should typi[INVESTIGATOR_360906] 
3 months after the original screen failure.  
 
7.3 Baseline (Vi sit 2)  
 Results from all screening procedures must be reviewed and all inclusion/exclusion criteria must 
be met prior to proceeding to baseline . Baseline visit will be scheduled 2 -4 weeks after the 
screening visit. If the baseline visit is scheduled  out-of-window (more than 4 weeks from 
screening ), approval to proceed  to the b aseline visit should be obtained from the project director  
and a rescreen may  be required . The baseline procedures may be completed over multiple 
days , but all assessments should be completed within seven days.  
 Vital signs  and weight  will be obtained , a nasal examination will be performed and concurrent 
medications and adverse events  will be documented.   
 Blood for plasma biomarkers will be collected immediately before participants undergo the 
optional lumbar puncture. Plasma insulin, glucose, Aβ40 and Aβ42 should  be measured in the 
morning  after an overnight fast, if possible . Additional plasma, along with serum and peripheral 
blood mononuclear cells (PBMCs) will be collected and banked. 
 
Cognitive and behavioral assessments will be performed  and study procedures will be 
standardized such that the ADAS- Cog12  will be  given first. Additional assessments include a 
memory composite (Story Recall and FCSRT ), an executive function test (Trail -making Test), 
the ADCS -MCI-ADL and the Neuropsychiatric Inventory (NPI) . A Research Satisfaction Survey 
will also be administered. Cognitive and behavioral assessments should not be administered 
while participants are fasting  or immediately after the LP p rocedure .   At s tudy visits during 
which fasting samples are collected on the same day that cognitive assessments are 
administered, a break and food should be given to participants in between the fasting  procedure 
and cognitive and behavioral assessments .  
 The optional l umbar puncture should  be performed in the morning after an overnight fast, if 
possible.  CSF samples will be used to measure levels of Abeta42, Abeta40, total tau, phospho -
tau181, i nsulin, F2 -Isoprostanes, cytokines, and BDNF . Additionally, CSF sample will be banked 
for future exploratory analysis. CSF will be collected and immediately frozen upright on dry ice 
for at least 20 minutes before being packaged along with the frozen plasma to be shipped 
overnight frozen on dry ice
 to the central b iomarker laboratory.. Site staff will call the participant 
within approximately 24 hours from the lumbar puncture procedure to inquire about the 
participant’s well being and possible adverse events.  
 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450020] information in the study diary . The 
participant and study partner will be instructed to bring any unused study drug and their study 
diary to the clinic at  each study visit (Month 3, 6, 9, 12, 15, 18 ) so that  study staff can assess 
study drug compliance.   
  
7.4 Month 3 (Visit 3 ) 
 The Month 3 visit is scheduled  three  months (+/- 2 weeks) from day one of the Baseline visit. At 
the Month 3 visit, the ADAS -Cog12  will be administered. The Research Satisfaction Survey will 
also be administered  Additionally, vital signs  and weight will be obtained , a nasal  examination 
will be conducted , adverse events and concurrent medications wi ll be recorded . Participants will 
bring their device, study diary and any used and unused study drug vials  to the site.  Study drug 
compliance will be assessed .  POD components (actuators, vial adapters, canisters and POD 
tips) will be dispensed..  
. 
 
7.5 Month 6 (Vi sit 4)  
 
The Month 6 visit is scheduled six months (+/- 2 weeks) from day one of the Baseline visit. At 
the Month [ADDRESS_450021], if possible. . Additional 
plasma, along with serum and peripheral blood mononuclear cells (PBMCs) will be collected 
and banked . Samples will be shipped frozen t o the central biomarker lab oratory  where the 
samples will be analyzed and banked. Additional blood for clinical laboratory evaluations will be 
conducted  to monitor safety and tolerability.   
 Cognitive and behavioral assessments will be performed  (during no n fasting session) . The study 
procedures will be standardized such that the ADAS- Cog12  will be the first cognitive 
assessment administered. Additional assessments include the MMSE, memory composite 
(Story Recall and FCSRT ), an executive function test (Trai l-making Test), CDR -SB, the ADCS -
ADL-MCI and NPI.  The Research Satisfaction Survey will also be administered.  
 
In addition, vital signs and weight will be obtained, physical, neurological and nasal 
examinations will be conducted,  adverse events and concur rent medications will be recorded .. 
Participants will bring their device, study diary and  any used and unused study drug vials  to the 
site.  Study drug compliance will be assessed.  POD components (actuators, vial adapters, 
canisters and POD tips) will be dispensed.   
 7.6 Month 9 (Visit 5)  
 
The Month 9 visit is scheduled nine months (+/ - 2 weeks) from day one of the Baseline visit.  At 
the Month 9 visit, the ADAS -Cog12  will be administered. In addition, vital signs  and weight will 
be obtained,  a nasal examinat ion will be conducted,  adverse events and concurrent medications 
will be recorded . Participants will bring their device, study diary and  any used and unused study 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 29 of 55
 drug vials  to the site  . Study drug compliance will be assessed.  POD components (actuators, 
vial adapters, canisters and POD tips) will be dispensed.    
 
7.7  Month 12  (Visit 6) 
 The Month 12 visit is scheduled 12 months (+/- 2 weeks) from day one of the Baseline visit.  
Month [ADDRESS_450022], if possible . Additional plasma, along with serum and peripheral 
blood mononuclear cells (PBMCs) will be collected and banked.  Clinical laboratory evaluations 
will be conducted  to monitor safety and tolerability.   
 The optional l umbar puncture should  be performed in the morning after a n overnight fast , if 
possibl e. Additionally, CSF sample will be banked for future exploratory analysis. CSF will be 
collected and immediately frozen upright on dry ice for at least 20 minutes before being 
packaged along with the frozen plasma to be shipped overnight frozen on dry ice
 to the central 
biomarker laboratory . Site staff will call the participant within  approximately  24 hou rs from the 
LP procedure to inquire about the participant’s well being and possible adverse events.  
 Cognitive and behavioral assessments will be performed . The study procedures will be 
standardized such that the ADAS- Cog12  will be the first cognitive test  administered. Additional 
assessments include the MMSE, a memory composite (Story Recall and FCSRT ), Trail-making 
Test A and B, the CDR -SB, the ADCS -ADL-MCI and the NPI. The Treatment Blinding 
Questionnaire and the Research Satisfaction Survey will also be  administered.  Cognitive and 
behavioral assessments should not be administered while participants are fasting or immediately after the LP procedure.  
 In addition, vital signs and weight will be obtained, physical, neurological and nasal 
examinations will be conducted,  adverse events and concurrent medications wi ll be recorded . 
Participants will bring their device  components, study diary and  any used and unused study 
drug vials  to the site .  Study drug compliance will be assessed. POD components (actuators,  
vial adapters, canisters and POD tips) will be dispensed.  
. Participants who were previously taking placebo will cross over to active study drug.   All 
participants will receive the active study drug during the six -month open -label period.  
  
 
7.8 Month 15 (Vis it 7, Open Label) 
 
The Month 15 visit is scheduled 15 months (+/ - 2 weeks) from day one of the Baseline visit. At 
the Month 15 visit,  the ADAS -Cog12  will be administered. In addition,  vital signs and weight will 
be obtained,  a nasal examination will be conducted,  adverse events and concurrent medications 
will be recorded . Participants will bring their device, study diary and  any used and unused study 
drug vials  to the site.    Study drug compliance will be assessed . POD components (actuators, 
vial adapters, canisters and POD tips) will be dispensed.  
 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 30 of 55
  
 7.9 Month 18  (Visit 8 , Open Label ) 
 
The Month 18 visit is scheduled 18 months  (+/- 2 weeks)  from day one of the Baseline visit. At 
the final Month [ADDRESS_450023], if possible .  Additional plasma, along with serum and peripheral 
blood mononuclear cells (PBMCs) will be collected and banked.  Clinical laboratory evaluations 
will be conducted  to monitor safety and tolerability.  
 
Cognitive and behavioral assessments will be performed  (during a non - fasting session). The 
study procedures will be standardized such that the ADAS- Cog12  will be the first cognitive test 
administered. Additional assessments  include the  MMSE, memory composite ( Story Recall and 
FCSRT ), Trail-making Test part A and B, CDR -SB, the ADCS- ADL-MCI and NPI. The Research 
Satisfaction Survey will also be administered.  
 
In addition, vital signs and weight will be obtained, physical, neurological and nasal 
examinations will be conducted,  adverse events and concurrent medications wi ll be recorded 
and study drug compliance will be assessed.  Participants will return their study diary, their Impel 
POD device components,  and any used and unused study drug vials to the clinic. Study drug 
compliance will be assessed during this final visit.  
 
8.0 EARLY TREATMENT/STUD Y DISCONTINUATION   
 
The investigators at each site will make every reasonable effort to maximize participant reten tion. However, if an investigator removes a participant from treatment or study, or if a 
participant declines further treatment or study participation, an Early Discontinuation Visit will be completed as soon as possible following discontinuation of the st udy drug and or at time of 
study discontinuation. The Early Discontinuation Visit will contai n the same assessments as the 
Month [ADDRESS_450024] 
LP or MRI was conducted, certain procedures may not be required at the Early Discontinuation Visit. If an in -person visit is not possible, site personnel will complete as much of the Early 
Discontinuation Visit as possible by [CONTACT_756]. All early treatment discontinuation participants 
will be s trongly encouraged to complete all remaining visits through Month 12  visit.  
 
8.1 Reasons for Early Discontinuation  
 
All reason(s) for treatment/study discontinuation will be collected using categories such as:  
• Adverse experience :  The participant has experien ced an adverse event that, in the 
opi[INVESTIGATOR_871], requires early termination. This may include abnormal laboratory 
values.  
• Death.  
• Safety risk : Any participant who becomes a safety risk during the trial will be withdrawn.   
• Protocol violation :  The participant fails to meet protocol entry criteria or did not adhere to 
protocol requirements.  
• Non-compliance: The participant is non -compliant with completion of study -related 
evaluations and or intake  of study drugs.  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 31 of 55
 • In the investigator’s judgment, it is in the participant’s best interest to discontinue 
participation in the treatment/study . 
• Consent is withdrawn .  The participant wishes to withdraw from the study, or the legally 
authorized representative wishes the participant to be withdrawn.  
• The study is terminated  by [CONTACT_360951].  
• Lost to follow up.   Participant could not be recalled back to conduct follow up visits.  
 
• Loss of informed study partner .  The participant no long er has a responsible study partner 
to oversee participant visits and administration of study drug. 
 
• Coordinating Center Request .  The Coordinating Center determines it is in the 
participant’s best interest to discontinue participation from the treatment  and or study.  
 
9.0 STUDY -SPECIFIC PROCEDURES  
 
9.1 Cognitive Evaluations  
 
9.1.1 Alzheimer’s Disease Assessment Scale -Cognitive (ADAS -Cog12) 
 The ADAS -Cog (Rosen, Mohs et al. 1984 ) is a psychometric instrument that evaluates memory, 
attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment.  Scores from the original portion of the test range from 0 (best) to 70 (worse) and then number of items not recalled ranging from [ADDRESS_450025] Recall  - a measure of epi[INVESTIGATOR_10682]  (Mohs, 
Knopman et  al. 1997) . The ADAS- Cog has been the primary cognitive instrument in previous 
and ongoing Alzheimer’s Disease  therapeutic  trials. Neuropsychometrists at each site are 
required to complete an ADAScog training and certification process. The person adminis tering 
this test should not also administer the CDR . 
 
9.1.2 Mini-Mental State Examinations (MMSE)  
 
The MMSE (Folstein, Folstein et al. 1975 ) is a brief, frequently us ed screening instrument for 
AD drug studies.  The MMSE evaluates orientation, memory, attention, concentration, naming, 
repetition, comprehension, and ability to create a sentence and to copy two overlappi[INVESTIGATOR_360907].  A lower score indicates more cogniti ve impairment.  The highest score is 30.   
 
9.1.3 Memory Composite (Story Recall and Free and Cued Selective Reminding Test ) 
 
A memory composite  measure combines  two epi[INVESTIGATOR_360908], immediate and 
delayed recall . Story Recall  is a test of contextual ver bal recall,  in which  participants listen to a 
story containing 44 informational bits that is read once. Participants  will be asked to recall the 
story immediately after the reading and after approximately  20-minute delay. Credit is awarded 
for each bit rec alled verbatim or accurately paraphrased. The previous results demonstrate the 
sensitivity of this task to changes in plasma insulin levels and intranasal insulin administration in adults with AD/MCI (Craft, Newcomer et al. 1996 ; Craft, Asthana et al. 1999 ; Craft, Asthana et 
al. 1999) .  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 32 of 55
  
The FCSRT (Grober et al. 198 8, 2008; Ferris et al. 2006) is a [ADDRESS_450026]  (Wechsler  Memory Scale -Revised ) 
 
Logical Memory Test I and II  (Delayed Paragraph Recall) used in this study is a modification of 
the epi[INVESTIGATOR_360909] -Revised (WMS -R) (Wechsler 
1987) . In this modified version, free  recall of one short story  that consists of 2 5 bits of 
information will be elicited immediately after it is read aloud to the participant  and again after a 
thirty -minute delay.  The total bits of information from the story that are recalled immediately 
(maximum score = 25) and after the delay interva l (maximum score = 25) are recorded. A 
retention or “savings” score can be computed by [CONTACT_360952].  
 
9.1.[ADDRESS_450027] (Part A and B) 
 Part A of the Trail -making tests (Reitan 1958 ) consists of [ADDRESS_450028] the circles in order as 
quickly as possible  (150 second maximum ). Part B consists of 25 circles, but these circles are 
either numbered (1 through 13) or con tain letters (A through L). Now the participant  must 
alternate between numbers and letters in an ascending order (e.g., 1 to A; 2 to B). The time to complete Part B (300 second maximum), adjusted for the time taken to complete Part A to 
control for sensori motor aspects of the task, is a sensitive measure of executive function and 
working memory.  
 9.2 Clinical and Functional Evaluations  
 
9.2.1 Clinic al Dementia Rating Scale – Sum of Boxes (CDR -SB) 
 
The CDR (Hughes, Berg et al. 1982 ; Morris 1993 ) is a clinical scale that rates the severity of 
dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, 
respectively). The score is based on interviews with the participant and study partner, using a 
structured interview that assesses six domains: memory, orientation, judgment and problem 
solving, community affairs, home and hobbies, and personal ca re.   
 
At Screening the CDR global score will be used for eligibility purposes. For all other 
administrations, the 6 domain scores will be summed to get the S um of Boxes  (SB) score. 
Training on the use of the CDR will be conducted to standardize its administration across sites. 
The CDR online training tool resides on the Washington University, St. Louis website, with 
oversight provided by [INVESTIGATOR_124]. John C . Morris  (Morris, Ernesto et al. 1997 ). The  person administering 
the CDR  should not also administer the ADAS -Cog12.  
 9.2.2 ADCS -MCI Activities of Daily Living (ADCS -ADL -MCI) 
 
The Alzheimer’s Disease Cooperative Study - Activities of Daily Living Scale (ADCS- ADL) is an 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 33 of 55
 activities of daily living questionnaire aimed at detecting functional decline in people with Mild 
Cognitive  Impairment (MCI) (Grundman, Petersen et al. 2004 ). It was adapted from an inventory 
developed by [CONTACT_360953]’s disease (Galasko, Bennett et al. 1997 ). In a structured interview format, informants are queried as to 
whether participant s attempted each item in the inventory during the prior [ADDRESS_450029] reliability. The questions focus 
predominantly on instrumental activities of daily living scales (e.g. shoppi[INVESTIGATOR_007], preparing mea ls, 
using household appliances, keepi[INVESTIGATOR_55228], reading).  
 9.2.3 Neuropsychiatric Inventory (NPI)  
 The NPI [CONTACT_832] a well -validated, reliable, multi -item instrument to assess psychopathology in AD 
based on interview with the study partner  (Cummings 1997 ). The NPI [INVESTIGATOR_360910] a nd severity of 10 neuropsychiatric disturbances.  Frequency assessments range 
from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe).  The overall score  and the 
score for each subscale are the product of severity and frequency.  
 9.2.4 Modified Hachinski  
 
This brief questionnaire incorporates questions about medical history, cognitive symptoms and features of stroke, reported by a study partner as well as the n eurological examination and 
neuroimaging studies  (Rosen, Terry et al. 1980 ).
 
 9.3 Research Satisfaction Survey  
 
A Research Satisfaction Survey will be administe red in order to evaluate the participant’s 
satisfaction with the current study. The survey will also reveal specific aspects of the study that 
participants may dislike, thus improvements can be made in the design of future studies. Past studies in multiple fields have also shown that consumer input and feedback is an important 
element in increasing retention (e.g., in psychotherapy) ( Duncan, Miller et al. 2010 ) (Miller, 
Duncan et al. 2005 ).  
 
9.4 Treatment  Blinding Questionnaire  
 
The Treatment  Blinding Questionnaire assess es the perception of blind being maintained until 
the end of the study.  The questionnaire is to be completed by [CONTACT_43038] y participant, study 
partner, principal investigator [INVESTIGATOR_360911].  
 10.0 STUDY  METHODS  
 10.1 Safety Assessments  
 
At each study visit, all participants will undergo a nasal  examination and any occurrence of 
adverse event s will be reviewed and documented ; concomitant medications will be recorded  as 
well. Physical  and neurological examination  and routine laboratory testing  will occur at 
Screening, Month 6, Month 12 and Month 18 visits. An MRI will be conducted at Screening and 
repeated at Month 12  for safety assessment. 
	Study staff will telephone each study participant 
who undergoes the optional lumbar puncture, or a person designated to speak for him/her, 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 34 of 55
 approximately 24 hours after the procedure to confirm the participan t’s well being and query 
about any new adverse events.   All adverse events will be reported to the DSMB. Safety  reports 
will be prepared and submitted to the DSMB for periodic review.  
 
10.2 Physical and Neurological Examination  
 
A brief physical examination wi ll be performed by a medically qualified professional every six 
months . A review of the major body systems will be performed for example: skin, 
head/ears/eyes/nose/throat (HEENT), cardiovascular, pulmonary, abdomen, musculoskeletal, neurological, and gastrointestinal. Assessments of height (Screening visit only), weight, and vital signs (systolic and diastolic blood pressure, pulse, temperature, and respi[INVESTIGATOR_1516]) are included.  
Neurological examination will include an assessment of cranial nerves, strength, c oordination, 
reflexes, sensation, tremor and gait at every study visit . 
 
A nasal examination will be performed every three months at each visit. The examination will 
assess irritation or other abnormalities of the nares.  
 10.3 Electrocardiogram (ECG)  
 
A standa rd 12 -lead resting ECG will be performed at Screening visit.  The ECG report will be 
reviewed, signed, and dated by [CONTACT_360954]  (or a medically qualified 
individual delegated by [CONTACT_978]) .  Those with clinically significant ECG find ings will be referred for 
follow -up as deemed appropriate by [CONTACT_360955] . 
  
10.4 Clinical Laboratory Evaluations  
 
All routine laboratory samples will be analyzed by a central laboratory, which will provide a 
procedures manual and supplies. Lab reports will be reviewed, signed and dated by [CONTACT_360956]  (or a medically -qualified individual delegated by [CONTACT_978]) .  If a value is 
outside of the laboratory’s normal range, the clinician  will indicate if it  is clinically significant or 
not. If clinically significant, lab tests may need to be repeated and follow up with the participant’s 
PCP should occur .    
 Clinical laboratory assessments include:
 
 
• Chemistry Panel  
• TSH 
• CBC | Differential  
• Vitamin B12  (Screeni ng visit only)  
• HCY | MMA (Note: HCY & MMA reflex tests are only run if the B12 level is <200 pg/m L) 
• HgA1c  
• U/A with microscopic (Screening visit only)  
 
11.[ADDRESS_450030] contraindications to lumbar puncture including 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 35 of 55
 prior lumbosacral  spi[INVESTIGATOR_79477], severe degenerative joint disease or deformity of  the spi[INVESTIGATOR_050], 
platelets <100,000 or a history of a bleeding disorder  cannot undergo a lumbar puncture in this 
trial, nor can participants who are taking anticoagulants, warfarin (Coumadin) and dabigatran 
(Pradaxa). Based on clinician j udgment and depending on the clinical indication, it may be 
suitable to discontinue participants from their anti -platelet agent (e.g., aspi[INVESTIGATOR_248], Plavix, NSAIDs) 
for [ADDRESS_450031] be conducted prior to initiation of study drug .  At 
Month 12, the optional lumbar puncture should be performed after (or more than 72 hours 
before) the MRI scan  while the participant is still actively taking study drug. Additionally, the time 
of the last INI dosage and the time of CSF collection will be recorded.  LP under fluoroscopy is 
allowed, if needed or required per local regulations .  A post lumbar puncture telephone follow -up 
call will be completed  approximately  24 hours after participant has undergone the procedure  to 
assess safety . 
 A minimal total volume of CSF ( 20 ml) will be collected from participants undergoing  the optional  
lumbar puncture  for this study.  To clear any blood from minor trauma associated with needle 
insertion, the first 1 -2 mL of CSF are discarded (or more if needed) .  Collected CSF is aliquoted 
into sterile  collection tubes. Approximately 2ml of CSF or volume per local laboratory 
requirements will be sent at ambient  temperature  to the local laboratory for protein, glucose and  
cell count. The remaining CSF will be shipped to the central biomarker laboratory.  CSF must be 
immediately frozen upright on dry ice for at least 20 minutes before being packaged and 
shipped overnight frozen on dry ice
 to the central biomarker laboratory. 
 
CSF samples will be used to measure levels of Abeta42, Abeta40, total tau , phospho -tau181, 
insulin, F2- Isoprostanes, cytokines, and BDNF.  Assays will be performed by [CONTACT_3433] e central 
biomarker laboratory . CSF samples will also be frozen and stored for future  analysis of putative 
biomarkers . 
 
11.2 Blood Collection  
 
Non-fasting blood samples will be collected at screening.  Fasting blood samples (Baseline, 
Month 6, Month 12, and Month 18)  should  be collected in the morning before breakfast and after 
an overnight fa st, if possible . 
 At Baseline and Month 12 visits , fasting blood samples should  be collected before CSF 
collection, which would be processed for fasting plasma , insulin, glucose, Abeta42, and 
Abeta40. Additional blood for plasma, serum and peripheral blood  mononuclear cells (PBMCs) 
will be collected. The samples will shipped to the central biomarker laboratory  for processing 
and banking.  
 11.3 Insulin & Glucose  (HgA1c Test ) 
 
HgA1c test will be performed  and fasting insulin and glucose values will be used to calculate the 
homeostasis model assessment of insulin resistance (HOMA -IR) for participants (Matthews, 
Hosker et al. 1985 ). A central laboratory will analyze the HgA1c test.  
 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 36 of 55
 11.4 Magnetic Resonance Imaging (MRI)  
 
Screening and Month 12  MRI will use the same imaging protocol, which will include a localizer 
scan, followed by a high- resolution 3D T1 structural series (MPRAGE or IR -SPGR), a T2 -
weighted series (FLAIR), a diffusion weighted scan and a gradient recalled echo scan. The  
volumetric analysis procedure will include corrections for gradient nonlinearities and intensity non-uniformity (Sled, Zijdenbos et al. 1998 ; Arnold, Liow et al. 2001 ; Jovicich, Czanner et al. 
2006) .  
 For clinical assessment of MR images and meeting of MRI screening criteria, images will be read by [CONTACT_360957], where quality checks will be performed. Images will be checked for image quality and adherence to scanning protocols. 3D T1 -weighted datasets passing quality checks 
will be corrected for spatial distortion and for intensity variation. Baseline and follow -up datasets 
for each participant will be spatially registered to one another using rigid -body registration 
followed by [CONTACT_360958]- brain and 
subregional volumetric change on a participant -by [CONTACT_84432].  
 MRI should be conducted prior to the LP. 1.5 Tesla (1.5T) or 3.0 Tesla ( 3T) scanners that have 
passed the study’s qualification procedures will be used. Participant s must be scanned by [CONTACT_360959].  
 11.[ADDRESS_450032] of the ApoE genotype 
on putative biomarkers of AD, clinical outcome measures, and adverse events . Participants will 
be asked to consent to optional DNA banking for future research studies.  ApoE genotypi[INVESTIGATOR_360912] .  
 
12.0 STATISTICAL PLAN  
 
The intent -to-treat (ITT) data set will include all eligible indi viduals who are randomized. The 
per-protocol (PP) data set will include all eligible participants who complet e 12-month 
assessments for the primary analysis and receive 80% of prescribed treatment doses. To address the Primary Aim, the longitudinal scores for the first 12 months on the primary endpoint 
(ADAS -Cog12) as well as Secondary Aims (memory composite , Trails, CDR -SB, ADCS -ADL-
MCI) , will be analyzed using random effects (RE) models to assess the differences in the rate of 
change across treatment groups (insulin -treated vs. placebo). Fixed effects for time, treatment 
and time -by-treatment interaction will be included. The following covariates will be included in 
efficacy analyses if they meet the criteria described below: baseline MMSE, baseline age, years of education, gender, APOE -ε4 carrier status, and diagnosis. Each covariate will be included in 
RE, ANCOVA, and GEE models only if the following two conditions are satisfied: 1) dissimilarity at baseline as measured by [CONTACT_3493]‘s exact test P < .1; 2) a  bivariate association exists between 
the covariate and the response (without regard to treatment) as measured by [CONTACT_4532]’s correlation coefficient P< 0.15.  
 To address Secondary  Aims 2 and 3, CSF biomarkers (Aβ42, tau, Aβ42/tau ratio) and MRI 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 37 of 55
 volumes (hi ppocampus, entorhinal cortex) will be analyzed with a similar strategy except that 
only baseline and month [ADDRESS_450033] for the interaction of Aβ42 and APOE -ε4 will also be included. 
Potential confounders evaluated as described above will also be included as main effects. RE 
models make use of all observed data, a nd the assumption is made that any missing data is 
missing at random. Responses will be modeled as multivariate normal.  Time will be treated as 
continuous and coded as months from baseline visit, (i.e. months = (exam date minus baseline 
date)/30.5]. The correlation structure for the model will be first order autoregessive. As 
sensitivity analyses, both GEE (generalized estimating equations) and ANCOVA modeling will be performed. As an additional secondary (sensitivity) analysis, the above RE analysis will be 
performed treating time as categorical; differences between the active group and placebo group 
at [ADDRESS_450034] squares means; this analysis does not 
assume linearity over time. Associated p -values, standard errors of the differences, and 95 
percent confidence intervals for each model will be presented for all analyses.  
 The application of the ITT principle in a change score analysis requires the imputation of any missing “post” observations. A multiple imputation strategy will be utilized for missing endpoints. 
Missing post -baseline data will be imputed via multiple imputations from the general location 
model  (Little and Rubin 1987 ). Point estimates, standard errors, confidence intervals, and p -
values will be computed using standard inference procedures for multiple imputations  (Little and 
Rubin 1987 ). Safety data will be analyzed using exact contingency table methods by [CONTACT_360960]. AEs will also be subcategorized by [CONTACT_8792] (unrelated/possibly 
related/probably related).   Details of the analytic models will be stated in a formal statistical 
analysis plan (SAP) that will be generated and finalized within six months of anticipated data  
lock.  12.[ADDRESS_450035] using the formula in Statistical 
Methods in Medical Research  (Armitage and Berry 1994 ). Sample sizes per arm were estimated 
using ADNI 12 -month change scores for the ADAS -Cog12 for the combined MCI and AD 
population, targeting power=.80, Type 1 error level=0.05, SD=5.[ADDRESS_450036] absolute change score differences between groups ranging from 
1.6-2.6 for dropout rates between 0.15-0.25. These estimates were derived with 6 month 
intervals between testing, and thus more frequent administration of the ADAS -Cog12 in this trial 
should provide even greater power. Similarly, a 4-mont h pi[INVESTIGATOR_4251] (Craft, Baker et al. 2012 ) 
dropout rate was <7%, and although a higher dropout rate is expected with a longer, multi -site 
trial, the excellent safety  profile and incentive of the open -label extension at the end of the trial 
should maximize retention. The addition of a delayed recall score should increase sensitivity for aMCI participant s. For MRI endpoints, sample sizes needed to detect a 25% slowing in mean 
rate of decline in the entorhinal cortex over a 12 -month period ranged from 70 for AD to 280 for 
aMCI  (Holland, Brewer et al. 2009 )
. Given that our n= 240-[ADDRESS_450037] adequate power.  
 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 38 of 55
 Table 5 | Range of estimates needed to detect absolute change score differences 
between groups ranging from 1.6- 2.[ADDRESS_450038] been extensively explored for over two decades ( Pontiroli, Alberetto et al. 1982 ). For diabetes 
treatment, absorption  enhancers must be used to increase the transport of insulin a cross the 
nasal membrane to the periphery due to the fact that peripheral bioavailablity of insulin without 
absorption enhancers is less than 1%  (Illum 2002 ). A recent safety study of  INI administration 
without absorption enhancers demonstrated no treatment  induced changes in blood glucose 
levels, nasal airway patency, or transnasal pressure gradient  (Kupi[INVESTIGATOR_23057], Sipi[INVESTIGATOR_360913]. 2003 ). There 
are no known serious risks associated with INI without enhancers. A recent industry report 
raised the issue of rare but significant increases in lung cancer in smokers treated with inhaled 
insulin; six of 4740 pa tients taking inhaled insulin developed lung cancer compared with one of 
4292 patients who received an active comparator  (incidence per 100 patient years exposure, 
0.13 vs 0.02). However, the inhaled insulin protocol used for diabetes treatment in this report included absorption enhancers to maximize delivery to lungs, whereas the nose -to-brain 
delivery device to be used in this study greatly minimizes lung delivery.  
 
Regarding the risk of hypoglycemia, at least five peer reviewed human studies  (Kern, Born et al. 
1999; Born, Lange et al. 2002 ; Kupi[INVESTIGATOR_23057], Sipi[INVESTIGATOR_360913]. 2003 ; Benedict, Hallschmid et al. 2004 ; 
Stockhorst, de Fries et al. Submitted for publication )  and four preliminary studies (Reger, 
Watson et al. 2006 ; Reger, Watson et al. 2008 ; Reger, Watson et  al. 2008) ( Craft, Baker et al. 
2012) revealed no change in blood glucose levels following intranasal insulin administration with 
doses that included 40 IU  4 times daily for two months. There was  one exception with the case 
of a single participant who experienced mild hypoglycemia (52 mg/dl) after skippi[INVESTIGATOR_007] a meal and 
engaging in sustained  vigorous exercise. In addition, a recent safety study (Kupi[INVESTIGATOR_23057], Sipi[INVESTIGATOR_360913]. 
2003) e xamined intranasal insulin administration of [ADDRESS_450039] patency and transnasal pressure gradient. Results indicated no change in blood glucose values with insulin, and no change in the frequency of  glucose values above 3.0 mmol/L. The only symptomatic 
hypoglycemic value occurred during placebo treatment. Insulin treatment had  no effect on other 
laboratory values (C -peptide, total cholesterol, HDL, LDL, triglycerides, creatinine, glutamyl 
transferase ), blood pressure, or body weight. In addition, nasal examinations revealed no 
adverse effects or functional disturbances following intranasal insulin administration. No serious 
adverse effects of treatment were observed in the preliminary studies  (Reger, Watson et al. 
2006; Reger, Watson et al. 2008 ; Reger, Watson et al . 2008; Craft, Baker et al. 2012 ). However, 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450040] such patterns and a conservative durat ion of treatment that balances safety and 
scientific considerations.  
 
13.2 Risks associated with use of the POD device  
 
There are risks that may occur from use of the investigational intranasal drug administration 
device, although these are not expected to be serious.  It is important that participant s carefully 
follow the instructions they are given about how to administer the study drug and how to 
maintain  the intranas al drug administration device  and its components . If they don’t carefully 
follow the instruct ions it is possible that they ma y not receive the correct dose.  They could also 
experience some discomfort to their eyes or face if they do not hold the device to their nose as 
directed. In addition, the contents of the POD device’s canister are under pressure and should not 
be punctured or stored near heat or open flame.  Finally, the POD tip on POD device is small and 
could be a choking hazard for children. The participant  and their Study Partner  will be trained on 
proper device operation and asked to maintain the device  and its components properly.   
 
13.3 Optional Lumbar Puncture 
 
Lumbar puncture may be associated with pain during the performance of the procedure. This is usually temporary and confined to the lower back. Headache may occur in about 5% of elde rly 
people who undergo lumbar puncture. Less commonly, in about 1 -4% of participants, a 
persistent low -pressure headache may develop, probably due to leakage of CSF. Lower rates of 
post-LP headache have been noted in elderly patients, and when atraumatic ( Sprotte) needles 
are used. If a post -LP headache persists it may need additional treatment, e.g. with fluids and 
analgesics. Uncommonly a blood patch (injection of some of the participant’s blood to patch the 
CSF leak) may be needed. Potential but rare ris ks of lumbar puncture include infection, damage 
to nerves in the back, and bleeding into the CSF space. The risk of these is much less than 1%.   
 13.[ADDRESS_450041] any medical contraindications for MRI,  which include metallic 
foreign bodies in the brain or eye or cardiac pacemaker. This safety screening is part of routine 
clinical practice at MRI centers and is performed before any participant is permitted to enter the 
scanning room.  There is a slight r isk of anxiety due to claustrophobia. Any participant who 
experiences anxiety when placed into the MR scanner will be removed from the scanner, 
offered reassurance by [CONTACT_224179], and offered the option of continuing or 
terminating the scan.  If the participant decides that the anxiety associated with MRI is 
uncomfortable for them and they wish to terminate the scan, then the examination will be ended at that time. There will be no attempt to coerce participants to complete exams that they are 
uncomfortable with.  Participants  uncomfortable with MRI scans should preferably not be 
included in this study. Use of anxiolytic agents for completion of MRI scans is discouraged, but 
allowed at the discretion of the site clinician.  
 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450042] the protocol at each site.  Details 
will be provided in the procedures manual.  
 
! Site Protocol Principal Investigator : [INVESTIGATOR_360914] (PI) is 
responsible for the overall conduct of the study at the site. The PI [INVESTIGATOR_360915]. The PI [INVESTIGATOR_360916] a  high level of skill and accuracy in 
conducting assessments. The PI [INVESTIGATOR_360917].  
! Study Clinician:  This person will be responsible for conducting and supervising the medical 
evaluation (nasal examination, physical and neu rological examinations), reviewing adverse 
events, interpreting laboratory results, and supervising clinical care provided to the 
participant during the protocol.  The study clinician will also perform the optional lumbar 
punctures.  The study clinician ma y perform the CDR -SB. The study clinician may be a 
physician, or if consistent with local practice and regulations, a nurse practitioner or physician’s assistant. The site Principal Investigator [INVESTIGATOR_360918].  
! Study Coordinator:  This person will be responsible for managing the day -to-day conduct of 
the trial.  Duties may include tracking recruitment, ensuring accurate administration of all 
instruments at the site, maintaining case report forms, processing of laboratory samples, 
maint aining a log of treatment adherence, serving as liaison with the clinical monitor, 
coordinating clinic visits, and administering cognitive assessments.  
! Interviewer/Psychometrician:  This person will be responsible for administering the 
cognitive and functi onal assessments.  The same individual should  not administer both the 
ADAScog and the CDR -SB. 
! CDR Rater:  This person wil l render the CDR -SB rating bas ed on clinical assessment of 
participant and study participant . Since the CDR -SB is a secondary outcome me asure, it is 
important for the CDR rater to remain blinded to ADA S-cog data.  
! ADAS -Cog12  Rater : This pers on should  be blinded to the CDR -SB data.  
! Regulatory  Affairs:  This person will be responsible for managing all regulatory related 
documents for the durat ion of the trial, including submitting all required regulatory and 
essential documents to the Coordinating Center  Regulatory Affairs.  
! Billing Remittance and Statement : This person will be responsible for reviewing and 
verifying payments from the Coordinati ng Center are in alignment with procedures 
completed, along with accepting and processing payments from the Coordinating Center . 
! MRI Contact : [CONTACT_360961],  for site qualification purposes and as 
needed to assess for drift . As well as conducting participant MRI scans per protocol.  
  
 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 41 of 55
 15.0 STUDY DRUG  
 
All participants will take two daily doses of INI (20 IU bid for a total of 40 IU daily) or placebo , 
adminis tered approximately [ADDRESS_450043] and dinner .  Participants should  be 
instructed to skip the morning dose of study drug  on study visit day s to avoid the acute effects of 
insulin . 
 
15.1 Humulin® R U- 100 Insulin  
 
Humulin® R U- 100 (NDC: 0002 -8215, Eli Lilly & Company)  is a polypeptide hormone structurally 
identical to human insulin synthesized through rDNA technology in a special non -disease -
producing laboratory strain of Escherichia coli bacteria. Humulin R U -100 has the empi[INVESTIGATOR_9506] C 257H383N65O77S6 and a molecular weight of 5808 Da. Humulin R U -100 is a sterile, 
clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, 
glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 
units) and water for injection. The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH.  
 More information about the Humulin
® R U- 100 insulin, including risks, contraindication and 
adverse reactions can be found in the the US package insert (USPI).  
 
15.2 Placebo (Sterile Diluent ) 
 
The matching placebo/sterile diluent  (NDC: 0002 -0800- 01, Eli Lilly & Company) will be 
comprised of : Glycerin, 16 mg; Metacresol, 1.6 mg; Phenol, 0.65 mg; Sodium Phosphate 
Dibasi c, 3.8 mg dissolved in 1 ml distilled water.  
  
15.3 Randomization  
 
We will use a semi -crossover design  (Jarjoura 2003 ). Initially, eligible participants will be 
randomized on a 1:1 schedule to receive placebo or 20 IU bid of INI using the following 
randomization strategy: ApoE -e4 carrier status (yes or no),  gender, MMSE score (high, low). 
Study site and age will be weighted in a covariate -adaptive randomization strategy to achieve 
optimal balance between treatment arms on important factors that may influence treatment outcome. After [ADDRESS_450044] and dinner. If a dose is missed, it should not be 
replaced. 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 42 of 55
  
15.6 Intranasal Administration  
 
The POD device specifically target s olfactory delivery to maximize  drug transport to the CNS by 
[CONTACT_291246] a measured insulin dose (0.1 mL) into a POD tip that rests inside the participant’s 
nostril.  The insulin or placebo is delivered by [CONTACT_360962] a propellant, delivering 10 IU to the upper nasal cavity  each time the device is activated for a total daily dose of 40 IU.   A pi[INVESTIGATOR_799] 
(Core H uman Factors, Inc., 2012) evaluating the usability and tolerability of the POD device 
demonstrated that participants preferred the POD device over a conventional nasal pump.    Participation of the study partner in the administration of the stud y drug is recommended for all 
participants  regardless of which device is used .
 If site clinicians determine that assistance is 
needed, study partners will participate in placing the study drug into the device  and 
administering the insulin  or placebo  twice  daily (after breakfast and dinner ). Participants and 
study partners will be trained in use of the delivery device. If the study partner is not available to 
assist with the administration of the study drug twice a day, another person (such as a family 
member or friend  or other) may be appropriate to assist the participant. The person (or persons) 
who assists  with the study drug administration must be properly trained prior to assisting.  
 15.7 Compliance  
 
Compliance will be assessed  by [INVESTIGATOR_2394]- site vial counts preferably during  each study visit . 
Participant s will be instructed to return their study diary and all used and unused study drug 
vials at each visit. Site personnel will count returned vials and evaluate compliance preferably  
while the participant  and study partner are s till on -site. Participant s found to be more than 20% 
noncompliant will receive specific instruction from site personnel, including re -instruction on 
study procedures and additional telephone contact [CONTACT_360963].  
 15.[ADDRESS_450045] ructions 
for a re -challenge . 
 
15.9 Breaking the Blind    
 In the case of an adverse event requiring treatment, sites will be directed to treat each 
participant as if he/she were receiving active study drug.  Decisions regarding breaking the blind 
must be made in  conjunction with the Project Director or Medical Director .  If the blind has been 
broken in any instance, the PI [INVESTIGATOR_360919]’s case 
report form: the date, the site personnel exposed to the treatment assignmen t, and the reason 
the blind was broken.   
 
15.10 Storage   
 
Participant and s tudy partners will be instructed to keep the study drug at a controlled 
temperature in the refrigerator . 
  
    
ADC -046-INI 
IND #: 119,[ADDRESS_450046] return all used, unused and partially  used study drug vials to the investigator.  
All returned study drug  vials will be accounted for  by [CONTACT_360964].   
 16.0 ADVERSE EVENTS  
 16.1 Definition  
 An adverse event (AE) is define d as per the Code of Federal Regulation Title 21 Part 312.  
 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32  
 
Adverse events which occur after informed consent is signed include but are not limited to: (1) 
worsening or change  in nature, severity, or frequency of conditions or symptoms present at the 
start of the study; (2) participant deterioration due to primary illness; (3) intercurrent illness; and 
(4) drug interaction. An abnormal laboratory value will only be reported as an AE if the 
investigator considers it to be an AE, or if it leads to the participant being withdrawn from the 
study.  
 
The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, and or other clinical information. In such cases, the diagnosis should be documented as the AE 
and not the individual signs or symptoms.  Symptoms and conditions present at the beginning of 
the study will be characterized, so that AEs can be defined as any new symptom, or any increase in frequenc y or severity of an existing symptom.  
 
Following questioning and evaluation, all AEs, whether determined to be related or unrelated to the study drug by a medically qualified site PI [INVESTIGATOR_360920] (MD, DO, NP or PA), must be 
documented in the participant’s medical records, in accordance with the investigator’s normal 
clinical practice, and on the AE e-CRF. Each AE is evaluated for duration, severity, seriousness, 
and causal relationship to the study drug.  
 16.[ADDRESS_450047] subsided, the 
conditions are considered medically stable, or the participants are no longer available for follow up. Participants who discontinue due to adverse experiences will be treated and followed 
according to established medical practice. All pertinent information will be entered into the e-
CRF. All adverse events  will be reported to the DSMB. Adverse events  will be rated as mild, 
moderate or severe.  This will also pertain to abnormal laboratory valu es deemed clinically 
significant by [CONTACT_7554] .  
 
17.0 SERIOUS ADVERSE EVEN TS (SAE)  
 17.1 Definition  
 A serious adverse event is defined as per the Code of Federal Regulation Title 21 Part 312  
 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsea rch.cfm?fr=312.32  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 44 of 55
  
17.2 Reporting SAEs  
 Any serious and adverse event due to any cause, which occurs during the course of the 
investigation (i.e. anytime after informed consent, regardless of study drug exposure) or within 
[ADDRESS_450048] Director and the Coordinating Center  within 24 hours of learning of the event. All serious 
adverse events  will be reported to the DSMB.  
 
18.0 ETHICS & REGULATORY CONSIDERATIONS  
 18.[ADDRESS_450049] 
 
Study investigators are charged with conducting this study in full conformity with: 
1. Good Clinical Practice (GCP) guidelines, as defined by [CONTACT_360965] (ICH) Guideline, Topic E6  
2. The [LOCATION_002] Code of Federal Regulations, Title 21, Part 50 (21CFR50) – 
Protection of Human Subjects  
3. 21CFR56 – Institutional Review Boards (IRBs)  
4. HIPAA  
5. State and Federal regulations and all other applicable local regulatory requirements and 
laws.    
 Study personnel involved in conducting this study will be qualified by [CONTACT_8640], training and 
experience to perform their respective task(s)  in accordance with GCP.   
 
18.[ADDRESS_450050] (IRB)  
 Each participating institution must provide for the review and approval of this protocol and  the 
associated informed consent documents and recruitment material by [CONTACT_360966] (OHRP). Any amendments to the 
protocol or consent materials must also be approved before they are placed into use. In the [LOCATION_002], only institutions holding a current US Federalwide Assurance issued by [CONTACT_200315]. 
 
 The investigator must obtain approval from the IRB for all subsequent protocol amendments 
and, when warranted, changes to the informed consent document. Protocol and informed 
consent form amendments can be made only with the prior approval of the Coordinating Center .  
The investigator may not implement any protocol deviation without prior notification to the 
Coordinating Cent er and prior review and documented approval of the IRB, except where 
necessary to eliminate an immediate hazard to study participants, or when change(s) involve only logistical or administrative aspects of the trial (ICH 4.5.4). The investigator shall notify the IRB of deviations from the protocol or serious adverse events occurring at the site, in 
accordance with local procedures.  
   
    
ADC -046-INI 
IND #: 119,232  
 
   Page 45 of 55
 18.3 Informed Consent & HIPAA Authorization  
 
In obtaining and documenting informed consent, the investigator should comply with the applicable regulatory requirement(s), and should adhere to GCP and to the ethical principles 
that have their origin in the Declaration of Helsinki.  Prior to the beginning of the trial, the 
investigator should have the IRB’s written approval of the written infor med consent form (ICF) 
and any other written information to be provided to participants.  Participants, their relatives, 
guardians, or authorized representatives and study partners will be given ample opportunity to 
inquire about the details of the study. Prior to a subject’s participation in the trial, the written 
informed consent form  and HIPAA Authorization should be signed and personally dated by [CONTACT_360967]/or the subject’s legally authorized representative, the study partner  and by [CONTACT_28506].  Participants should be provided a 
copy of the signed ICF.  
 
The informed consent will not only cover consent for the trial itself, but for the genetic research, 
biomarker studies, biological sample storage and imaging scans as well. The consent for storage will include consent to access stored data, biological samples, and imaging data for 
secondary analyses. Consent forms will specify that DNA and biomarker samples are for 
research purposes only; the tests on the DNA and biomarker samples are not diagnostic in 
nature and participants will never receive results. MRI scan findings of clinical significance, determined by [CONTACT_360968], can be shared with participants  per site clinician discretion .  
 Consent for ms will be developed by [CONTACT_360969] (PD) . The sample consent form includes all of the required elements of informed 
consent required by [CONTACT_360970] . Once developed and approved by [CONTACT_941] P D, the sampl e is 
sent to sites participating in the protocol where it is tailored to include site -specific information as 
well as to meet local IRB consent form regulations. Each site’s PI, under the guidance of his/her 
IRB, is responsible for ensuring that all applic able state laws are met with regards to judgment 
of competency and the consent form process. Each study site must submit its letter of IRB -
approval and the approved consent form to  Regulatory Affairs at the Coordinating Center  along 
with other required reg ulatory records and essential documents in order to be approved to 
receive s tudy drug/ supplies and enroll participants into this study. During the first monitoring 
visit following participant  enrollment, the clinical monitors will review the consent forms and 
verify that the proper signatures have been obtained.  
 
18.4 Participant  Confidentiality | HIPAA  
 Participant confidentiality is strictly held in trust by [CONTACT_3486], research staff, 
and the sponsoring institution and their agents.  Thi s confidentiality is extended to cover testing 
of biological samples and genetic tests in addition to the clinical information relating to 
participants. The study protocol, documentation, data and all other information generated will be 
held in strict conf idence.  No information concerning the study or the data will be released to any 
unauthorized third party, without prior written approval of the sponsoring institution. Authorized 
representatives of the Coordinating Center  may inspect all documents and rec ords required to 
be maintained by [CONTACT_737], including but not limited to, medical records (office, clinic or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study.  The clinical study site will permit access to such records. Any data, specimens, forms, reports, and other records that leave the site will be identified only by a subject identification number to maintain confidentiality.  
All records will be kept in a locked file cabinet.  All computer entry and networking programs will be done using subject IDs only. Information will not be released without written permission of 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450051] of 1996 (HIPAA).  Those regulations require a signed HIPAA A uthorization informing the subject  of the following:  
 
• What protected health  information (PHI) will be collected from participants in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research participant to revoke their authorization for use of their PHI.  
 In th e event that a subject  revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject  
authorization. Each site PI, under the guidance of his/her IRB, is responsible for ensuring that all 
applicable HIPAA regulations and State laws are met.  
 
19.0 GENETIC RESEARCH & STORAGE OF GENETIC M ATERIAL  
 
The DNA is banked in locked freezers in the ADCS  Biomarker  Core  at UCSD.  Sample tubes 
are bar -coded and linked to part icipant ID number only and banked without personal identifiers . 
The presence of the sample is recorded into a computerized inventory database that  is 
encrypted and password- protected.  
 
Only DNA from consenting participants will be banked and used to facilitate future research on 
aging and dementia, particularly in the discovery of genetic polymorphisms that may influence 
risk of developi[INVESTIGATOR_201314].  Collecti on of  DNA will permit qualified investigators to probe candidate 
genetic polymorphisms as predictors of ou tcome in future studies.  The samples will be stored 
by [CONTACT_360971].  If funding should lapse completely, the UCSD ADRC will provide responsible custodianship of the ADCS biospecimen bank.  
  
An online request form is available through the ADCS website for investigators wishing to 
access DNA samples stored by [CONTACT_360972].  Specific procedures for requesting samples for 
future genetic studies have been prepared by [CONTACT_360973].  These DNA guidelines 
were developed in accordance with the American Society for Human Genetics’ position paper 
on the NBAC report and the Ad Hoc Committee on Stored Tissue of the College of American Pathologists.  
 19.1 Storage of Biospecimen Samples  
 
All biospecimens being  banked for future AD biomarker research will be shipped to and stored 
by [CONTACT_360974].  
 20.0 RISKS AND BENEFITS ASSOCIATED WITH THIS STUDY  
 
20.1 Potential Benefits of the Prop osed Research to Human Subjects  
 
There is an urgent need to identify promising treatments for patients with AD and its prodrome aMCI. In a previous trial  (Craft, Bak er et al. 2012 ), intranasal insulin safely improved delayed 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450052], the relatively minor  risks posed by [CONTACT_360975], cognitive testing, MRI 
and LP are outweighed by [CONTACT_360976]. 
 
20.2 Inclusion of Women and Minorities  
 
There are currently no studies that definitively support o r negate the existence of significant 
differences in response to intranasal insulin in subgroups defined by [CONTACT_360977]. A specific goal percentage for  women and minority enrollment is not set for this 
study. However, we will  monitor minori ty enrollment  throughout the study  and make special 
effort to encourage minority enrollment . Minority enrollment will be  facilitated through minority 
outreach effort coordinated by [CONTACT_360978] . Each site will be encouraged to employ specific efforts (e.g. media and 
community outreach activities) to attract appropriate minority participant s to the trial. Spanish 
translation is available for a variety of instruments deployed in this trial. The succes s of minority 
recruitment is based on the specific efforts of each site (e.g. media and community outreach efforts) as well as the criteria for entry. This trial has been designed to maximize minority 
participation in both ways. No participant  will be excl uded due to his or her  sex, race, or ethnic 
group.  
 No studies have been completed that examine racial or ethnic differences in response to 
treatment with intranasal insulin. One study has been published examining gender differences in 
which 32 healthy participants were administered 160 IU regular human insulin or placebo 
intranasally; acute effects on cognitive performance were examined as outcomes. Their findings 
indicated that women showed the most cognitive benefit on hippocampal -dependent measures, 
and no sex differences on hippocampal -independent tasks (Benedict, Kern et al. 2008 ). 
Although this one s tudy provides only modest  support for sex differences, the current study will 
conduct secondary analyses designed to detect significant differences in intervention effect between sexes.  
 
20.3 Inclusion of Children as Participants in Research Involving Human Subjects  
 Children will not be included.  
 
21.0 STUDY MONITORING & DATA COLLECTION  
 Clinical monitors  are responsible for contact[CONTACT_360979], upon request, inspecting various records of the trial (e.g., case 
report forms and other pertinent data).   
 
Clinical  monitors are  responsible for inspecting the online case report forms at regular intervals 
throughout the study to verify adherence to the protocol, completeness and accuracy of the 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450053] this study 
for audit.  Inspection of site facilities (e.g., pharmacy, laboratories) and review of study -related 
records will occur to evaluate the trial conduct and compliance with the protocol, GCP, and 
applicable regulatory requirements.  
 
Results of locally administered tests such as ECG tracings and local clinical laboratory reports 
must  be retained as source documents.  
 No study document shall be destroyed without prior written agreement between the 
Coordinat ing Center  and the investigator.  Should the investigator wish to assign study records 
to another party or move them to another location, he/she may do so only with the prior notification and written consent of the A TRI/RA.  
 
21.1 Communication Plan & Site M onitoring  
 
Communication between the PI, the Coordinating Center , and the sites will occur through 
several mechanisms. Sites will communicate performance data to the clinical operations team , 
Regulatory Affairs  and the Clinical M onitoring group s on an ongoing basis. These statistics will 
be reported during bi -weekly conference calls attended by [CONTACT_941] P D and the study team . Sites will 
also receive formal monitoring visits approximately twice yearly in which all ongoing trial 
operations and source documents are reviewed. Visit finding information  is provided to the PI, 
following each monitoring visit . 
 22.0 DATA AND SAFETY MONI TORING PLAN AND BOAR D 
 
The Medi cal and Safety Core  will be responsible for medical management of the trial including 
standardized coding of AEs and central medical monitoring. Safety reports will be created for 
the DSMB  on a quarterly basis. Operations Core personnel will generate any aggregate 
summary tables, as needed, to the PI  [INVESTIGATOR_360921]/reporting 
obliga tions to the FDA, their respective site IRBs, as well as to the NIA, and other oversight and 
regulatory agencies. The Data Safety and Monitoring Board will monitor this trial. No 
investigator involved in the trial is a member of the DSMB. The initial task of the DSMB will be to 
review the protocol to identify any necessary modifications. If modifications are necessary, revisions will be re viewed by [CONTACT_360980]. 
The DSMB, based on its review of the protoc ol, will identify the data parameters and format of 
the information to be regularly reported. The DSMB will be informed of the occurrence of any serious adverse events and immediately notified of fatal or life threatening events. The DSMB 
may at any time r equest additional information from the study PI. The DSMB will initially be 
provided with data blinded to treatment status, but they may request unblinded data if there is a 
safety concern. The DSMB and NIA  representative  will meet in person or by [CONTACT_360981] 
a quarterly basis. Based on the review of safety data, the DSMB will make recommendations regarding the conduct of the study. These may include amending safety  monitoring  procedures, 
modifying the protocol or consent, terminating the study or co ntinuing the study as designed. 
The Board will also be informed in a real -time basis of all immediately reportable AE (FDA 
defined serious AE). All reports are stripped of identifying information. These processes ensure  
substantial oversight and case review to alert the investigators, in a timely manner, to any safety 
    
ADC -046-INI 
IND #: 119,[ADDRESS_450054] of the Protocol Committee,  
interested Principal Investigators and appropriate Coordinating Center  personnel .  The 
committee will solicit input and assistance from other Investigators as appropriate and adhere to all Coordinating Center  Publications Policies.  
 24.0 CLINICAL TRIAL REGISTRATION & SHARING OF FINAL RESEARCH DATA  
 This trial has been registered on www.ClinicalTrials.gov  (NCT 01767909).  
 
Data from this research will be shared with other researchers pursuant to the 02/26/2003 “NIH 
Final Statement on Sharing Research Data”.  The research grant contains a data sharing policy 
consistent with the goals of the NIH but which also respects the rights of commercial partners.  NIH believes that dat a sharing is important for further translation of research results into 
knowledge, products, and procedures to improve human health.  The NIH endorses the sharing 
of final research data to serve these and other important scientific goals.  To protect subjects’ 
rights and confidentiality, identifiers will be removed from the data before they are shared.  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 50 of 55
 25.0 TABLE 4: SCHEDULE OF PROCEDURES AND ASSESSMENTS 
 
Visit # 1 2 3 4 5 6 7 8 
Visit Name/Month  Screen Baseline  3 6 9 12 15* 18* 
         
Informed Consent  X        
Demographics  X        
Medical History  X        
Concomitant Meds X X X X X X X X 
Nasal Exam  X X X X X X X X 
Physical and Neurological Exam  X   X  X  X 
Vital Signs X X X X X X X X 
Height  X        
Weight  X X X X X X X X 
ECG  X        
Modified Ha chinski  X        
Logical Memory II Subscale 
(Wechsler Memory Scale)  X        
ADAS- cog12   X X X X X X X 
MMSE  X   X  X  X 
Memory Composite (Story Recall, 
FCSRT )  X  X  X  X 
Trail-making Test ( Part A & B)  X  X  X  X 
ADCS- ADL-MCI  X  X  X  X 
NPI  X  X  X  X 
CDR X   X  X  X 
Treatment  Blinding Questionnaire       X   
Research Satisfaction Survey   X X X  X  X 
Adverse Events X X X X X X X X 
Urinalysis  X        
Blood Draw  X X  X  X  X 
- Clinical Labs  X   X  X  X 
- ApoE Genotypi[INVESTIGATOR_007] | DNA 
Banking1 X        
- Biomarkers | Serum | PBMCs  
| Sample Banking  X  X  X  X 
Optional LP  X    X   
- CSF Biomarkers  | Banking2  X    X   
- post-procedure safety 
telephone check   X    X   
MRI X3     X   
INI Device Training   X       
Distribute replacement POD device 
componen ts   X X X X X  
Study Diary Return   X X X X X X 
Drug Compliance    X X X X X X 
Return of devices and components         X 
*Open Label visits  
1DNA banking is optional  
2CSF banking is optional  
3Screening MRI to be conducted after confirmation from clinic ian that the participant has met inclusion/exclusion criteria  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 51 of 55
 26.0 LITERATURE CITED  
 
Aisen, P. S., S. Andrieu, et al. (2011). "Report of the task force on designing clinical trials in 
early (predementia) AD." Neurology  76(3): 280 -286. 
Alber t, M. S., S. T. Dekosky, et al. (2011). "The diagnosis of mild cognitive impairment due to 
Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup." Alzheimers Dement . 
Armitage, P. and G. Berry (1994) . Statistical methods in medical research . Oxford, [LOCATION_011], 
Blackwell Scientific Publications.  
Arnold, J. B., J. S. Liow, et al. (2001). "Qualitative and quantitative evaluation of six algorithms 
for correcting intensity nonuniformity effects." Neuroimage  13(5): 931 -943. 
Baker, H. and R. F. Spencer (1986). "Transneuronal transport of peroxidase -conjugated wheat 
germ agglutinin (WGA -HRP) from the olfactory epi[INVESTIGATOR_360922]." 
Exp Brain Res  63(3): 461 -473. 
Baker, L. D., D. J. Cross, et a l. (2011). "Insulin resistance and Alzheimer -like reductions in 
regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes." Arch Neurol  68(1): 51 -57. 
Balin, B. J., R. D. Broadwell, et al. (1986). "Avenues for entry of peripherally administered 
protein to the central nervous system in mouse, rat, and squirrel monkey." J Comp 
Neurol  251(2): [ADDRESS_450055], C., M. Hallschmid, et al. (2004). "Intranasal insulin improves memory in humans." 
Psychoneuroendocrinology  29(10): [ADDRESS_450056], C., W. Kern, et al. (2008). "Differential sensitivity of men and women to anorexigenic 
and memory- improving effects of intranasal insulin." J Clin Endocrinol Metab  93(4): 
1339- 1344.  
Bodian, D. and H. A. Howe (1941). "Expe rimental studies on intraneuronal spread of 
poliomyelitis virus." Bull Johns Hopkins Hosp  68: 248 -267. 
Born, J., T. Lange, et al. (2002). "Sniffing neuropeptides: a transnasal approach to the human 
brain." Nat Neurosci  5(6): 514 -516. 
Broadwell, R. D. and B . J. Balin (1985). "Endocytic and exocytic pathways of the neuronal 
secretory process and trans -synaptic transfer of wheat germ agglutinin- horseradish 
peroxidase in vivo." J Comp Neurol  242(4): 632 -650. 
Cavanna, A. E. and M. R. Trimble (2006). "The precune us: a review of its functional anatomy 
and behavioural correlates." Brain  129(Pt 3): 564 -583. 
Chiu, S. L., C. M. Chen, et al. (2008). "Insulin receptor signaling regulates synapse number, 
dendritic plasticity, and circuit function in vivo." Neuron  58(5): 7 08-719. 
Core Human Factors, Inc. for Impel Neuropharma (2012).  "Usability and Tolerability Testing of 
the Pressurized Olfactory Delivery (POD) Device: 1 -40. 
Craft, S., S. Asthana, et al. (1999). "Enhancement of memory in Alzheimer disease with insulin 
and somatostatin, but not glucose." Arch Gen Psychiatry  56(12): 1135 -1140.  
Craft, S., S. Asthana, et al. (1999). "Insulin metabolism in Alzheimer's disease differs according 
to apolipoprotein E genotype and gender." Neuroendocrinology  70(2): 146 -152. 
Craft, S., L. D. Baker, et al. (2012). "Intranasal insulin therapy for Alzheimer disease and 
amnestic mild cognitive impairment: a pi[INVESTIGATOR_29833]." Arch Neurol  69(1): 29 -38. 
Craft, S., L. D. Baker, et al. (2012). "Intranasal Insulin Therapy for AD and MCI: A  Pi[INVESTIGATOR_360923]." Arch Neurol  69: 29 -38. 
Craft, S., J. Newcomer, et al. (1996). "Memory improvement following induced hyperinsulinemia 
in Alzheimer's disease." Neurobiol Aging  17(1): 123 -130. 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 52 of 55
 Craft, S., E. Peskind, et al. (1998). "Cerebrospi[INVESTIGATOR_360924]'s 
disease: relationship to severity of dementia and apolipoprotein E genotype." Neurology  
50(1): 164 -168. 
Craft, S. and G. S. Watson (2004). "Insulin and neurodegenerative disease: shared and specific 
mechanisms." Lancet Neurol  3(3): 169 -178. 
Cummings, J. L. (1997). "The Neuropsychiatric Inventory: assessing psychopathology in 
dementia patients." Neurology  48([ADDRESS_450057] 6): S10 -16. 
De Felice, F. G., M. N. Vieira, et al. (2009). "Protection of synapses against Alzheimer's -linked 
toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers." Proc Natl 
Acad Sci U S A 106(6): 1971 -1976.  
Duncan, B. L., S. D. Miller, et al. (2010). The heart and soul of change: Delivering what works in 
therapy, American Psychological Association.  
Faber, H. K. (1938). "The early lesions of poliomyelitis after intranasal inoculation." J Pediat  
13(1): [ADDRESS_450058] (1930). "The pathogenesis of, and propagation of the virus 
in, experimen tal poliomyelitis." J Path Bact  33: 17 -45. 
Ferris S .H., Aisen P .S., et al.  (2006).  " Alzheimer’s Disease Cooperative Study Group. ADCS 
Prevention Instrument Project: overview and initial results."  Alzheimer Dis Assoc Disord  
20(4)(suppl3): S109 -S123.  
Folstein, M. F., S. E. Folstein, et al. (1975). "Mini -mental state". A practical method for grading 
the cognitive state of patients for the clinician." J Psychiatr Res  12(3): 189 -198. 
Francis, G. J., J. A. Martinez, et al. (2008). "Intranasal insulin prevents  cognitive decline, 
cerebral atrophy and white matter changes in murine type I diabetic encephalopathy." 
Brain  131(Pt 12): 3311 -3334.  
Frey, W. H. (2002). "Intranasal delivery: By[CONTACT_360982]- brain barrier to deliver therapeutic 
agents to the brain and  spi[INVESTIGATOR_1831]." Drug Delivery Technology  2(5): 46 -49. 
Frolich, L., D. Blum -Degen, et al. (1998). "Brain insulin and insulin receptors in aging and 
sporadic Alzheimer's disease." J Neural Transm  105(4 -5): 423- 438. 
Galasko, D., D. Bennett, et al. (1997). "An inventory to assess activities of daily living for clinical 
trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study." Alzheimer 
Dis Assoc Disord  [ADDRESS_450059] 2: S33 -39. 
Gasparini, L., G. K. Gouras, et al. (2001). "Stimulation of beta -amyloid precursor protein 
trafficking by [CONTACT_360983] -amyloid and requires mitogen -activated 
protein kinase signaling." J Neurosci  21(8): 2561 -2570.  
Gil-Bea, F. J., M. Solas, et al. (2010). "Insulin levels are decreased in the cerebrospi[INVESTIGATOR_360925]'s disease." J Alzheimers Dis  22(2): 405 -413. 
Grillo, C. A., G. G. Pi[INVESTIGATOR_342813], et al. (2009). "Insulin -stimulated translocation of GLUT4 to the plasma 
membrane in rat hippocampus is PI3 -kinase dependent." Brain Res  1296: 35 -45. 
Grober, E., H. Buschke, et al. (1988). "Screening for dementia by [CONTACT_360984]." Neurology  
38(6): 900 -903. 
Grober E ., Hall C .B., et al.  (2008) . "Memory impairment, executive dysfunction, and intellectual 
decline in preclinical Alzheimer’s disease. "  J Int Neuropsych Soc  14(2):  266-278. 
Grossman, M., J. Farmer, et al. (2005). "Cerebrospi[INVESTIGATOR_360926]'s disease." Ann Neurol  57(5): 721 -729. 
Grundman, M., R. C. Petersen, et al. (2004). "Mild cognitive impairmen t can be distinguished 
from Alzheimer disease and normal aging for clinical trials." Arch Neurol  61(1): [ADDRESS_450060], et al. (2008). "Obese men respond to cognitive but not to catabolic 
brain insulin signaling." Int J Obes (Lond)  32(2): 275 -282. 
Holland, D., J. B. Brewer, et al. (2009). "Subregional neuroanatomical change as a biomarker 
for Alzheimer's disease." Proc Natl Acad Sci U S A  106(49): [ZIP_CODE] -[ZIP_CODE].  
    
ADC -046-INI 
IND #: 119,232  
 
   Page 53 of 55
 Hong, M. and V. M. Lee (1997). "Insulin and insulin -like growth factor -1 regulate tau 
phosphorylation in cultured human neurons." J Biol Chem  272(31): [ZIP_CODE] -[ZIP_CODE].  
Hughes, C. P., L. Berg, et al. (1982). "A new clinical scale for the staging of dementia." Br J 
Psychiatry  140: 566 -572. 
Illum, L. (2002). "Nasal drug delivery: new devel opments and strategies." Drug Discov Today  
7(23): 1184 -1189.  
Impel NeuroPharma.  "A drug- device compatibility and functionality veritification of the Impel 
NeuroPharma clinical Precision Olfactory Delivery device and the Novolog® insulin 
formulation."  Imp el Document CD -1304- 003, 2015.  
Jack, C. R., Jr., M. Slomkowski, et al. (2003). "MRI as a biomarker of disease progression in a 
therapeutic trial of milameline for AD." Neurology  60(2): 253 -260. 
Jarjoura, D. (2003). "Crossing controls to treatment in repeat ed-measures trials." Control Clin 
Trials  24(3): 306 -323. 
Jovicich, J., S. Czanner, et al. (2006). "Reliability in multi -site structural MRI studies: effects of 
gradient non- linearity correction on phantom and human data." Neuroimage  30(2): 436 -
443. 
Kern, W ., J. Born, et al. (1999). "Central nervous system effects of intranasally administered 
insulin during euglycemia in men." Diabetes  48(3): 557 -563. 
Kristensson, K. and Y. Olsson (1971). "Uptake of exogenous proteins in mouse olfactory cells." 
Acta Neuropat hol 19(2): 145 -154. 
Kupi[INVESTIGATOR_23057], A., J. Sipi[INVESTIGATOR_23057], et al. (2003). "Intranasally administered insulin intended for prevention of 
type 1 diabetes--a safety study in healthy adults." Diabetes Metab Res Rev  19(5): 415 -
420. 
Larsen, D. L., C. C. Attkisson, et al. (1979) . "Assessment of client/patient satisfaction: 
development of a general scale." Eval Program Plann  2(3): 197 -207. 
Lee, C. C., Y. M. Kuo, et al. (2009). "Insulin rescues amyloid beta -induced impairment of 
hippocampal long- term potentiation." Neurobiol Aging  30(3): 377 -387. 
Liu, Y., Johnson, M, et al. (2008).  "Creation of a Standardized Geometry of the Human Nasal  
Anatomy."  J Appl Physiol 106: 784 -795. 
Little, R. J. A. and D. B. Rubin (1987). Statistical analysis with missing data . [LOCATION_001], Wiley.  
Maes, O.  C., H. M. Schipper, et al. (2009). "Methodology for discovery of Alzheimer's disease 
blood- based biomarkers." J Gerontol A Biol Sci Med Sci  64(6): 636 -645. 
Matthews, D. R., J. P. Hosker, et al. (1985). "Homeostasis model assessment: insulin resistance 
and beta- cell function from fasting plasma glucose and insulin concentrations in man." 
Diabetologia  28(7): 412 -419. 
McKhann, G. M., D. S. Knopman, et al. (2011). "The diagnosis of dementia due to Alzheimer's 
disease: Recommendations from the National Institute on Aging and the Alzheimer's 
Association workgroup." Alzheimers Dement . 
Miller, S. D., B. L. Duncan, et al. (2005). "The partners for change outcome management 
system." J Clin Psychol  61(2): 199 -208. 
Minoshima, S., K. A. Frey, et al. (1995). "Preserved p ontine glucose metabolism in Alzheimer 
disease: a reference region for functional brain image (PET) analysis." J Comput Assist 
Tomogr  19(4): 541 -547. 
Minoshima, S., R. A. Koeppe, et al. (1994). "Anatomic standardization: linear scaling and 
nonlinear warpi[INVESTIGATOR_360927]." J Nucl Med  35(9): 1528 -1537.  
Mohs, R. C., D. Knopman, et al. (1997). "Development of cognitive instruments for use in clinical 
trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden i ts scope. The Alzheimer's Disease Cooperative Study." Alzheimer Dis Assoc 
Disord  [ADDRESS_450061] 2: S13 -21. 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 54 of 55
 Morris, J. C. (1993). "The Clinical Dementia Rating (CDR): current version and scoring rules." 
Neurology  43(11): 2412 -2414.  
Morris, J. C., C. Ernesto, et a l. (1997). "Clinical dementia rating training and reliability in 
multicenter studies: the Alzheimer's Disease Cooperative Study experience." Neurology  
48(6): 1508 -1510.  
Petersen, R. C., P. S. Aisen, et al. (2010). "Alzheimer's Disease Neuroimaging Initiati ve (ADNI): 
clinical characterization." Neurology  74(3): 201 -209. 
Pontiroli, A. E., M. Alberetto, et al. (1982). "Insulin given intranasally induces hypoglycaemia in 
normal and diabetic subjects." Br Med J (Clin Res Ed)  284(6312): 303 -306. 
Reger, M. A., G. S. Watson, et al. (2006). "Effects of intranasal insulin on cognition in memory -
impaired older adults: modulation by [CONTACT_15335]." Neurobiol Aging  27(3): 451 -458. 
Reger, M. A., G. S. Watson, et al. (2008). "Intranasal insulin administration dose -dependently 
modulates verbal memory and plasma amyloid -beta in memory -impaired older adults." 
Journal of Alzheimers Disease 13(3): 323 -331. 
Reger, M. A., G. S. Watson, et al. (2008). "Intranasal insulin improves cognition and modulates 
beta- amyloid in early AD." Neurology  70(6): 440 -448. 
Reitan, R. M. (1958). "Validity of the trail making test as an indicator of organic brain damage." 
Perceptual & Motor Skills  8(3): 271 -276. 
Rivera, E. J., A. Goldin, et al. (2005). "Insulin and insulin -like growth factor expression  and 
function deteriorate with progression of Alzheimer's disease: link to brain reductions in 
acetylcholine." J Alzheimers Dis  8(3): 247 -268. 
Rosen, W. G., R. C. Mohs, et al. (1984). "A new rating scale for Alzheimer's disease." Am J 
Psychiatry  141(11): 1 356-1364.  
Rosen, W. G., R. D. Terry, et al. (1980). "Pathological verification of ischemic score in 
differentiation of dementias." Ann Neurol  7(5): 486 -488. 
Rubin, D. B. (1987). Multiple Imputation for Nonresponse in Surveys . Hoboken, New Jersey, 
John Wile y & Sons, Inc.  
Sakane, T., M. Akizuki, et al. (1995). "Direct drug transport from the rat nasal cavity to the 
cerebrospi[INVESTIGATOR_872]: the relation to the molecular weight of drugs." J Pharm Pharmacol  
47(5): 379 -381. 
Sano, M., R. Raman, et al. (2011). "Adding Delayed Recall to the Alzheimer Disease 
Assessment Scale is Useful in Studies of Mild Cognitive Impairment But Not Alzheimer Disease." Alzheimer Dis Assoc Disord  25(2): 122 -127. 
Schneider, L. S., R. E. Kennedy, et al. (2010). "Requiring an amyloid -beta1- 42 biomarker for 
prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials." Alzheimers Dement  6(5): 367 -377. 
Selkoe, D. J. (2008). "Soluble oligomers of the amyloid beta -protein impair synaptic plasticity 
and behavior." Behav Brain Res  192(1): 106 -113. 
Shipley, M. T. (1985). "Transport of molecules from nose to brain: transneuronal anterograde 
and retrograde labeling in the rat olfactory system by [CONTACT_360985] -horseradish 
peroxidase applied to the nasal epi[INVESTIGATOR_2130]." Brain Res Bull  15(2): 129 -142. 
Sled, J. G., A. P. Zijdenbos, et al. (1998). "A nonparametric method for automatic correction of 
intensity nonuniformity in MRI data." IEEE Trans Med Imaging  17(1): 87 -97. 
and its CNS effects in healthy humans : unconditioned and conditioned responses."  
Stockhorst, U., D. de Fries, et al. (2004). "Insulin and the CNS: effects on food intake, memory, 
and endocrine parameters and the role of intranasal insulin administration in humans." Physiol Behav  83(1): [ADDRESS_450062], U., D. de Fries et al. (2011).  "Unconditioned and conditioned effects of intranasally 
administered insulin vs placebo in healthy men:  a randomised controlled trial."  Diabetologia  54(6): 1502- 06. 
    
ADC -046-INI 
IND #: 119,232  
 
   Page 55 of 55
 Talairach, J. and P. Tournoux (1988). Co-planar stereotaxic atlas of the human brain: 3 -
dimensional proportional system: an aproach to cerebral imaging . [LOCATION_001], [LOCATION_001], 
Thieme Medical Publishers.  
Thorne, R. G., C. R. Emory, et al. (1995). "Quantitative analysis of the olfactory pathway for 
drug delivery to the brain." Brain Res  692(1 -2): 278- 282. 
Thorne, R. G., G. J. Pronk, et al. (2004). "Delivery of insulin -like growth factor -I to the rat brain 
and spi[INVESTIGATOR_360928]." Neurosci ence 127(2): 481 -496. 
Townsend, M., T. Mehta, et al. (2007). "Soluble Abeta inhibits specific signal transduction 
cascades common to the insulin receptor pathway." J Biol Chem  282(46): [ZIP_CODE] -[ZIP_CODE].  
Turner, R. S. (2003). "Biomarkers of Alzheimer's disease a nd mild cognitive impairment: are we 
there yet?" Exp Neurol  183(1): 7 -10. 
Vemuri, P., H. J. Wiste, et al. (2009). "MRI and CSF biomarkers in normal, MCI, and AD 
subjects: predicting future clinical change." Neurology  73(4): 294 -301. 
Wechsler, D. (1987). WM S-R Wechsler Memory Scale - Revised Manual . [LOCATION_001], The 
Psychological Corporation, Harcourt Brace Jovanovich, Inc.  
Weiss, P. and Y. Holland (1967). "Neuronal dynamics and axonal flow, ii. The olfactory nerve as 
model test object." Proc Natl Acad Sci U S A 57(2): 258 -264. 
Worsley, K. J., A. C. Evans, et al. (1992). "A three -dimensional statistical analysis for CBF 
activation studies in human brain." J Cereb Blood Flow Metab  12(6): 900 -918. 
Zhao, L., B. Teter, et al. (2004). "Insulin- degrading enzyme as a downstream target of insulin 
receptor signaling cascade: implications for Alzheimer's disease intervention." J 
Neurosci  24(49): [ZIP_CODE] -[ZIP_CODE].  
Zhao, W. Q. and M. Townsend (2009). "Insulin resistance and amyloidogenesis as common 
molecular foundation for type 2 diabetes and Alzheimer's disease." Biochim Biophys 
Acta 1792(5): 482 -496. 
  